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According to the World Health Organization, breast cancer is by far the most frequently 
diagnosed cancer, and the most frequent cause of cancer death among women in the world. 
Tobacco smoking is the single largest cause of cancer worldwide and has been linked to 
cancer in most organ systems. The association between breast cancer and smoking has been 
debated for decades, and more than 150 epidemiological studies have been conducted in this 
field, with various conclusions. The aim of this thesis was to illuminate the association 
between smoking and breast cancer incidence, mortality, and to study the socioeconomic 
consequences of smoking-associated breast cancer in a large Norwegian cohort with a high 
number of female smokers. The cohort included 302,865 women recruited from three large 
Norwegian health surveys, and is one of the largest cohorts that exists today. During 14 years 
of follow-up we identified 7490 cases of breast cancer, and 1106 breast cancer deaths. The 
main analyses compared ever smokers to never smokers. In Paper I we investigated the 
association between active smoking and breast cancer incidence. We found an increased risk 
of 15% for ever smokers overall, as well as an increased breast cancer risk with increasing 
number of cigarettes smoked per day, smoking duration, number of pack-years smoked, and 
lower age at smoking initiation. We found an increasing risk with longer smoking duration 
before first childbirth, and no increased risk among those who started to smoke after first 
childbirth. In Paper II we investigated the association between smoking and breast cancer 
mortality, which revealed a 15% increased risk of breast cancer mortality for ever smokers. 
Most of the results for the different smoking exposures considered were not statistically 
significant. In particular, no statistically significantly increased breast cancer mortality was 
found for women who initiated smoking before first childbirth. In Paper III, we used level of 
education as a validated measure of socioeconomic status, and investigated whether level of 
education had an impact on the risk of smoking-associated breast cancer. We did not find an 
increased risk of smoking-associated breast cancer in women with high level of education, but 
we were able to confirm that smoking before first childbirth remains a risk factor for breast 
cancer, regardless of educational achievement. Smoking-associated breast cancer does not 
seem to have an important impact on social inequalities in health. This thesis confirms the 
weak, but significant association between smoking and breast cancer observed in recent 
cohort studies. Furthermore, weak but significantly increased breast cancer mortality was 





associated breast cancer. Active smoking, in particular active smoking before first childbirth, 
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In 1999, the World Health Organization arranged the first international conference on women 
and tobacco use.1 The growing knowledge on smoking-associated diseases such as cancer, 
chronic obstructive pulmonary disease and cardiovascular disease, together with the rising 
epidemic of tobacco use among women and youths, drew attention to the need for gender-
specific tobacco control strategies for the 21st century.  
 
The available knowledge on the relationship between tobacco smoking (hereafter referred to 
simply as smoking) and a variety of human cancers is based primarily on epidemiological 
evidence.2 In 1950, the landmark study by Richard Doll investigated the incidence of lung 
cancer among medical doctors who were smokers. This study led to the definition of tobacco 
as a carcinogenic substance.3 Indeed, Doll’s study found an increasing risk of lung cancer 
with increasing number of cigarettes smoked; an observation that was controversial at the 
time, but that was later confirmed in numerous studies.  
 
The scientific conclusions of a causal association between smoking and cancer, as well as 
between smoking and other diseases, are the result of an ever-increasing body of scientific 
evidence and have been the object of constant conflict between the scientific community and 
the tobacco industry. Smoking is the leading preventable cause of death globally,4 and the 
World Health Organization expects one billion smoking related deaths to occur in the 21st 
century.5  
 
In this thesis we wanted to study the associations between active smoking and breast cancer 
incidence and mortality, and to examine if smoking-associated breast cancer may have an 
impact on socioeconomic differences in health. 
 
4.1 The four-stage model of the smoking epidemic 
In 1994, Lopez and colleagues described a four-stage model of the smoking epidemic in 
developed countries.6 This model illustrates the substantial time lag between smoking 
initiation and smoking-associated death, and shows that the health consequences of smoking 








Figure 1: The four-stage model of the smoking epidemic. From Lopez et al. (1994).6 Reprinted with 
permission.  
 
In Figure 1, stage 1 illustrates the beginning of the smoking epidemic in 1900, when the 
smoking prevalence was less than 20%, smokers were mostly men, and smoking had caused 
few deaths. Stage 2 illustrates a rapid increase in male smoking prevalence towards a peak of 
40% to 80% in 1950, the start of the main increase in female smoking prevalence and the start 
of the main increase in smoking-associated mortality. Stage 3 illustrates a flattening and 
convergence in smoking prevalence among male and female smoking prevalence, while 
smoking-associated mortality rose from 10% to about 30% of all deaths, mostly in men. Stage 
4 illustrates a continued increase in smoking-associated mortality, peaking at about 1/3 of all 
deaths among men, with a smaller proportion among women. This figure illustrates that the 
health consequences of smoking depend on smoking prevalence in the population and that 
these consequences will occur later in women, as they joined the smoking epidemic later than 
men. This fact is important when studying the consequences of smoking for women, and 







An updated report suggested that in the future the four-stage model should be applied to each 
gender separately, especially in less developed countries (Figure 2).7 However, the main 
message stands: the time lag between smoking initiation and smoking-associated mortality is 
universal and not gender-, nor society-specific. 
 
 
Figure 2: Stages of the worldwide smoking epidemic, modified for female smokers. From Thun et al 
(2012).7 Reprinted with permission. 
 
This time lag implies that the real health consequence of smoking among women can only be 
seen in studies with a long follow-up period, which could partly explain why previous studies 
on breast cancer and smoking did not reveal any significant association.  
 
4.2 Smoking in Norway 
In 1973, 43% of young women (16-24 years of age) and 32% of all women (16-74 years of 







Figure 3: Prevalence (%) of female current smokers aged 16-74 years in Norway, 1973-2013. From 
Statistics Norway.8 Reprinted with permission. 
 
The smoking prevalence among Norwegian women has changed substantially during the past 
decades.9 Figure 4 shows that in the birth cohorts 1920-1944, smoking prevalences of 35% 
and 50% were observed in 1940 and 1970, respectively. The prevalence peaked in the late 
1960s, when female current smokers represented more than 50% of the 1940-1944 birth 
cohort. Between 1970 and 2000 the prevalence stabilized at around 32%. A large decrease in 
current smokers occurred after 2000, and today only 12% of women aged 16-24, and 16% of 
all women are current smokers.10 Age at smoking initiation has also declined gradually in the 












Figure 4: Prevalence of female smokers in 5-years birth cohorts (1890-1964) in the period 1910-1995. 




Figure 5: Age at smoking initiation in different birth cohorts in Norway (cumulative percent). Norway`s 
Public Reports, 2000:16. Y-axis: smoking prevalence (percent). X-axis: age at smoking initiation.9 Reprinted 
with permission. 
 
Smoking patterns also reveal socioeconomic differences, as there is a higher proportion of 
current smokers among women with a lower level of education. These women also have an 
earlier age at smoking initiation, use more harmful smoking products, and have a lower 
frequency of smoking cessation than women with a higher level of education. Women with a 





5 The epidemiology of breast cancer  
5.1 Introduction 
Breast cancer is the most common cancer among women worldwide in terms of both 
incidence and mortality. Indeed, breast cancer accounts for 25% of all female cancers, with 
1.7 million new cases and 0.5 million deaths globally.5 About 55% of all new breast cancer 
cases are diagnosed in the developing world, and this incidence is rapidly increasing. The 
etiology of breast cancer is multifactorial, involving endocrine and reproductive factors.5 In 
general, the high breast cancer rates in developed countries are the consequence of a higher 
prevalence of known risk factors, many of which – early age at menarche, low parity, late age 
at first childbirth, exposure to exogenous hormones, and late age at menarche – relate to 
estrogen exposure in breast tissue.11 At least three major mechanisms have been suggested to 
explain how estrogens might cause breast cancer,10 but the understanding of this process 
remains incomplete. 
 
In Norway, breast cancer represents 22% of all new cancer cases in women, with 2956 new 
cases reported to the Cancer Registry of Norway in 2012.12 Breast cancer incidence in 
Norway has increased gradually since the introduction of mammography screening in the 
1990s. A decline in breast cancer incidence was seen for the first time between 2005 and 







Figure 6: Trends in breast cancer incidence and mortality in Norway and 5-year relative survival. Cancer 
Registry of Norway, 2014.12 Breast cancer incidence: red line. Breast cancer mortality: pink line. Reprinted with 
permission. 
 
Breast cancer is the third most common cause of cancer mortality in Norway, after lung and 
colon cancer, with 645 deaths among woman in 2012. In Norway, as in many other developed 
countries, breast cancer mortality has declined since the early 1990s, most likely due to 
increased breast cancer awareness, improvement in treatment, and increasing screening 
coverage5, 12-15 (Figure 6). Establishing multi-disciplinary management teams has provided 
optimization of breast cancer care in many developed countries. However, large inequalities 
exist in worldwide breast cancer survival, with 84% survival in the United States compared to 
30% in Bhopal, India.16 There are also lingering differences according to cancer stage at 
diagnosis.16  
 
5.2 Key points 
When performing prospective studies on the consequences of smoking-associated health 
problems, there are some issues to be aware of:  
• Due to the long latency period between smoking initiation and development of disease, a 





• Smoking prevention programs have led to a reduction in smoking prevalence in many 
developed countries in recent years. However, the consequences of smoking will still be 
seen for decades due to the aforementioned time lag. 
• Smoking prevalence is decreasing in most developed countries, but increasing in many 
less developed countries 
• Because smoking is very common and breast cancer is a common disease, even the 
smallest increase in risk conferred by smoking may have a great impact on breast cancer 
incidence from a population perspective. 
 
5.3 Active smoking and breast cancer incidence 
Altogether more than 150 epidemiological studies, both case-control and cohort studies, have 
been performed on the association between active smoking (hereafter referred to as smoking) 
and breast cancer.2 Since 2004, most cohort studies have reported a weak, but significantly 
increased risk of breast cancer among current (between 9% and 32%) and former smokers 
(between 5% and 18%).17-27 Cohort studies are usually given more weight than case-control 
studies, as the cohort study design avoids the possibility of recall bias.  
 
Eight national and international consensus reviews have been published on active smoking 
and breast cancer risk.2, 28-34 The evidence of an association between breast cancer and active 
smoking has been inconsistent, leading to past conclusions that smoking was not a risk factor 
for breast cancer.35-37 The monograph Tobacco smoke and involuntary smoking was published 
by the International Agency for Research on Cancer (IARC) in 2004. It concluded that there 
was a causal relationship between smoking and cancers of the lung, oral cavity, nasal cavity 
and paranasal sinuses, nasopharynx, oropharynx, hypopharynx, larynx, esophagus, stomach, 
pancreas, liver, kidney, ureter, urinary bladder, cervix, and myeloid leukemia. Moreover, they 
concluded that there was a lack of carcinogenicity for cancers of the breast and 
endometrium.30 The same year, the report of the United States Surgeon General concluded 
there was “no causal relationship between active smoking and breast cancer”.33  
 
In 2005, the California Environmental Protection Agency concluded that the weight of the 
evidence (including toxicology of environmental constituents, epidemiological studies and 
breast biology) was consistent with a causal association between environmental tobacco 





in 2009 by the Canadian Expert Panel on Tobacco Smoke and Breast Cancer Risk32 was the 
first to thoroughly analyze the current scientific data for both active and passive smoking and 
breast cancer according to many of the known measures of smoking exposure, such as 
smoking duration, pack-years, age at smoking initiation, and smoking in relation to first 
childbirth. This report concluded that the relationship between active smoking and breast 
cancer is consistent with causality. The IARC Monograph Volume 100E, published in 2012, 
reviewed more than 150 epidemiological studies on this association. They found that all large 
cohort studies since 2002 consistently showed a small positive association, with relative risks 
(RRs) between 1.1 and 1.3, and concluded that there is limited evidence that smoking causes 
breast cancer.2 In the 2014 report, the United States Surgeon General was still reluctant to 
conclude that a causal association exists between smoking (active or passive) and breast 
cancer.34  
 
Several recent meta-analyses and reports have evaluated the association between smoking 
before first childbirth and the increased risk of breast cancer.26, 32, 34, 38 The Canadian Report 
concluded that the available data suggest an association between active smoking before first 
childbirth and an increased risk of breast cancer.32 A meta-analysis published in 2011 
included 23 papers with the aim to investigate the association between smoking before first 
childbirth and breast cancer, and concluded that a causal association between smoking and 
breast cancer was unlikely.38 The authors revealed a 10% (95% CI 1.07-1.14) increase in the 
risk of breast cancer among women who initiated smoking before first childbirth compared 
with never smokers, but considered that the overall risk increase was too small to be 
categorized as a positive association. Another meta-analysis published in 2013 by Gaudet and 
colleagues included 15 cohort studies and found an increased risk of 21% (95% CI 1.14-1.28) 
for the same association. They concluded that their study supported the suggestion that 
smoking before first childbirth increases breast cancer risk.26 A meta-analysis presented in the 
2014 United States Surgeon General report found a 16% significantly increased risk for breast 
cancer and smoking before first childbirth (HR=1.16, 95% CI 1.12-1.20) when nine recent 
cohort studies were included.34  
 
The results of these recent meta-analyses showed a significant increased risk of breast cancer 
when comparing women who smoked before their first childbirth with never smokers, but 
their conclusions were different. However, these studies did not consider their results 





smoking exposure, which is essential. In the large cohort studies from 2013, the highest risks 
were found among women who smoked the most before their first childbirth.25, 26, 39 Smoking 
in the period before first childbirth emerges as a risk factor for breast cancer. 
 
An overview of most of the cohort studies on smoking and breast cancer incidence published 
since 2004 is included in the appendix.  
 
5.4 Smoking and breast cancer mortality  
Several studies have been performed on smoking with death from breast cancer, as outcome. 
However, most papers studying the association between smoking and breast cancer mortality 
assessed smoking status (current/former) during, or after breast cancer diagnosis instead of 
before diagnosis.40-47   
 
Assessments of smoking exposure before or after breast cancer diagnosis are fundamentally 
different, as a survival study looks at the period from diagnosis to death (often considering the 
effect of treatment), whereas a mortality study may look at the number of overall deaths 
during a certain time period.48  A mortality study may consider the period before diagnosis 
(during cancer development) together with the period after diagnosis. Some papers do not 
clearly point out these differences, which may sometimes confuse the reader. 
 
One of the first studies on smoking and breast cancer mortality was the report from the 
Cancer Prevention Study II (1994) carried out in the United States. They found a 26% 
statistically significantly increased breast cancer mortality among current smokers and a non-
significantly reduced mortality among former smokers, as compared to never smokers.51 
Later, the report by Pirie and colleagues from the Million Women Study found a 13% 
significantly increased risk of breast cancer mortality associated with current smoking.52  
A 2013 short report from the Woman’s Healthy Eating and Living (WHEL) study in the 
United States, which included 2953 women and 249 breast cancer deaths during 7.3 years of 
follow-up, found breast cancer mortality to be non-significantly increased when smoking 
exposure (current/former) was assessed at breast cancer diagnosis. The authors did a similar 
analysis among women with high number of pack-years before breast cancer diagnosis, as a 
proxy for lifetime smoking exposure, and found a significantly increased mortality of 54% in 





study including three cohorts from the United States (1059 breast cancer deaths during 11 
years of follow-up) found a 54% significantly increased breast cancer mortality among former 
smokers with a lifetime smoking exposure of more than 35 pack-years, and a non-
significantly increased mortality for those with a lifetime smoking exposure of less than 35 
pack-years.54 Current smokers in this study had a mean exposure of 39 pack-years, and 
revealed a 61% significantly increased risk for breast cancer mortality. 
These recent papers on smoking and breast cancer-associated mortality found an increased 
risk when assessing lifetime smoking exposure, but not when analyzing by smoking status 
(never, former, current, ever). 
 
An overview of some of the cohort studies on smoking and breast cancer mortality is included 
in the appendix. 
 
5.5 Female smoking, level of education and breast cancer  
Inequalities in health among groups with different socioeconomic status (as measured by level 
of education, occupation and income), constitute one of the main challenges for public health 
authorities. The direction of the socioeconomic gradient varies between cancer sites. Among 
women, it tends to be negative for lung, stomach, esophagus and cervical cancer, while a 
positive association has been observed for malignant melanoma, colon, ovary and breast 
cancer.55, 56 At the same time, differences in smoking habits remain one of the main 
explanations for socioeconomic inequalities in health.  
 
In recent decades, the magnitude of smoking exposure in Norway has changed substantially 
between different socioeconomic groups. During the early stages of the smoking epidemic, 
smoking was more common among groups with a high level of education.9 This situation 
changed in the 1960s, when smoking prevalence increased among those with a lower level of 
education. A similar pattern was observed in many Northern European countries, and in the 
United Kingdom.57  
 
Smoking among women worldwide is increasing and the age at smoking initiation among 
women seems to be equal to that among men.4, 58-60 Today, smoking is more common among 
those with a lower level of education, and as a consequence, smoking has become an indicator 





of smoking-associated health problems in women, and in those with lower socioeconomic 
status can be expected in the future.59 Today, breast cancer is more common among women 
with a high level of education, and smoking is more common among women with a lower 
level of education. As smoking emerges as a possible risk factor for breast cancer, a more 






6 Concepts of causality for smoking and breast cancer 
 
How can we determine if there is a causal association between smoking and breast cancer?  
In 1965, Hill attempted to distinguish causal from non-causal associations. His considerations 
of causality are still widely used as guideline when judging evidence in epidemiological 
studies,62, 63 though other guidelines have also been suggested.64  
 
6.1 Biological plausibility  
Smoking has been established as carcinogenic to humans, leading to increased risk of cancer 
incidence and mortality from many cancer types.5, 30, 52 The IARC has found more than 70 
carcinogenic chemicals in tobacco smoke,30 a number of which are also found in human 
breast tissue.65 Thus an association between smoking and breast cancer is biologically 
plausible. A relatively weak association between smoking and breast cancer, as compared to 
other cancers such as lung cancer, may be due to the fact that a relatively low dose of the 
carcinogens found in tobacco smoke can be found in human breast tissue.65 
 
Difficulties in finding associations between smoking and breast cancer were commonly 
explained by the anti-estrogenic effect of smoking,35, 66 in which the low level of blood 
estrogens in smokers was thought to oppose the carcinogenic effects of tobacco smoke. 
Previous epidemiological studies observed an earlier age at menopause,67 a higher risk of 
osteoporosis,68 a lower risk of endometrial cancer,69, 70 and possibly a lower postmenopausal 
mammographic density among smokers.71 Recent studies have found a positive association 
between level of blood estrogens, progesterone and androgens, and both pre- and 
postmenopausal breast cancer.72, 73 One of these studies on postmenopausal breast cancer 
revealed a higher level of blood estrogens in heavy smokers,72 which was in contrast with 
previous assumptions.74 Hence the increased level of blood estrogens in smokers may be an 
important observation when explaining the increased risk of breast cancer that has been 
reported in most cohort studies carried out since 2004. 
 
6.2 Consistency 
Since 2004, at least 12 studies17-20, 22-27, 38, 39, 75, 76 have consistently reported an increased risk 





the majority of these studies reported a significant association. Several large reports and meta-
analyses have also been done, with conclusions on the association ranging from “no causal 
relationship”33, 38 to “the association between smoking and breast cancer is consistent with 
causality”32 to “…support the hypothesis that active smoking increases breast cancer risk”.26 
The last citation comes from the latest report from the United States Surgeon General (page 
283), which claims insufficient convincing evidence for a causal association, stating “the 
evidence is suggestive but not sufficient to infer a causal relationship between active smoking 
and breast cancer”.34 The scientific evidence is still not consistent enough to generate a 
consensus on the causal association between smoking and breast cancer. 
 
6.3 Specificity 
The criterion for specificity for active smoking and breast cancer is a major challenge when 
assessing smoking-associated diseases such as breast cancer. Indeed, breast cancer is a very 
heterogeneous disease and does not have only one cause. Smoking affects the risk of a 
number of diseases, accurately portraying the lack of specificity of this exposure.  
 
6.4 Dose-response relationship 
The RRs for the associations between active smoking and breast cancer are not as high as for 
many other smoking-associated diseases, which makes the conclusion of a causal association 
even more difficult. However, this lack of evidence of causality must take into consideration 
that cancer development often takes decades.2 Long latency periods between initial exposure 
and disease makes long a follow-up period necessary if valid conclusions are to be drawn. 
 
Previous studies often assessed smoking as a simple binomial variable, i.e., smoking/non-
smoking, without considering different measures of smoking exposure. Recent studies have 
found higher lifetime smoking exposures, i.e., longer smoking duration, higher number of 
cigarettes smoked per day, and/or higher number of pack-years, to be important for this 
association, indicating that breast cancer risk increases with increasing dose-response, and 







6.5 Strength of the association 
Breast cancer incidence is high in many populations that have a high smoking prevalence, but 
there is no scientific evidence linking smoking to high breast cancer incidence in any 
population. The associations found for smoking and breast cancer are weak, and as 
mentioned, any causal association is still under debate.  
 
In general, large studies allow for better precision, but are not necessarily better due to 
problems of validity (e.g., chance of selection bias and confounding). Large studies yield low 
p values and more narrow CIs.77 Importantly, p values and CIs relate to precision, not validity, 
which in most cases will be the most relevant factor when determining the quality of a study. 
Power directly depends on the number of observed events, and there is an indirect relationship 
between power and sample size, which arises because more subjects usually means more 
events.78  
 
Some epidemiologists are cautious when interpreting the results of cohort studies that show 
weak associations between an outcome and an exposure (hazard ratio [HR] between 2 and 
0.5) due to the high risk of bias that comes with weak associations.79 Nevertheless, public 
health researchers must consider weak associations as they may have important impacts in a 
large population or in populations where the exposure is common. A high RR risk increases 
the chance of causality; however, a low RR should not be immediately interpreted as a lack of 
causality. For this reason, identifying associations with low RRs may have important 
consequences from a public health perspective. 
 
6.6 Temporality 
Temporality refers to the necessity that the cause precedes the effect. This criterion is 
inarguable.80 For this reason, studies on breast cancer incidence consider the smoking 
exposure that occurred before breast cancer diagnosis.  
 
6.7 Experimental confirmation 
Based on in vitro studies, Russo and colleagues hypothesized that smoking is more likely to 
induce neoplastic changes in the human breast in the period between menarche and first 





studies revealed that the human breast undergoes a series of changes from birth, through 
puberty, childbirth and lactation. During puberty breast tissue changes from a predominantly 
ductal structure to a lobular structure with different histological lobular subtypes thanks to the 
introduction of numerous endogenous and exogenous hormones. Russo named the different 
lobular subtypes according to their degree of differentiation: Lobules 1, Lobules 2, Lobules 3, 
and the fully differentiated Lobules 4. The most common type of breast cancer, ductal 
carcinoma, originates in Lobules 1 in rodents. After childbirth, a period of active cell 
proliferation takes place and the lobular composition progresses to Lobules 2, Lobules 3, and 
Lobules 4 subtypes. After the lactation period, Lobules 3 remains the dominant structure until 
the fourth decade of life. When compared with parous women, the number of Lobules 1 in 
nulliparous women remains higher until after menopause. Experimental and biological studies 
suggest that Lobules 1 is biologically different than the other subtypes, and might exhibit 
different susceptibility to carcinogenesis. This may constitute a biological explanation as to 
why exposure to carcinogens before first childbirth may cause breast cancer later in life, and 
why childbirth protects against breast cancer. Timing of smoking has now emerged as one of 
the most important risk factors in the development of breast cancer, with breast tissues being 
the most vulnerable to smoking in the period between menarche and first childbirth. This has 






7 Aims of the thesis 
 
I. To study the association between active smoking and breast cancer incidence 
 
II. To study the association between active smoking and breast cancer mortality 
 
III. To examine if smoking-associated breast cancer is associated with social inequalities 






8 Materials and methods 
 
8.1 Study population 
The study population in all papers comprised 302,865 Norwegian women born between 1899 
and 1975, participating in three large prospective cohort studies conducted by the National 
Health Screening Service (now the Norwegian Institute of Public Health): the Norwegian 
Counties Study (1974-1988), the 40 Years Cohort (1985-1999) and the Cohort of Norway 
(CONOR, 1994-2003) hereafter referred to as the surveys. The study population was followed 
for 14 years on average. We identified 7490 breast cancer cases and 1106 breast cancer-
associated deaths during the follow-up period. The earliest surveys were initiated due to the 
high prevalence of cardiovascular disease in Norway; the methods for these surveys were 
adapted and further developed and improved based on experience gleaned from the Oslo I 
study (1972-1973).  
 
Individuals were selected by age group and/or by county of residence, in order to obtain a 
representative sample of the Norwegian population. They then received an invitation and 
baseline questionnaire by mail, which were to be completed before attending the first health 
examination at the screening facility. The baseline questionnaire included detailed 
assessments of smoking habits, physical activity, and other lifestyle factors. The health 
examination included a physical examination, during which anthropometrics such as height 
and weight were obtained in a standardized manner by a trained nurse to avoid bias. In some 
surveys individuals received a second questionnaire at the first health examination, which 
could be completed either immediately or later at the individual’s home. The average 
response rates varied between 56% and 88% in the included surveys.84 
 
8.1.1 The Norwegian Counties Study  
This survey was carried out in three Norwegian counties (Finnmark, Sogn og Fjordane, 
Oppland), and consisted of three rounds of health examinations carried out during the periods 
1974-1978, 1977-1983, and 1985-1988. The first round included all residents aged 35-49 
years in addition to a random sample of 10% of the general population aged 20-34 years. The 





similar protocols and questionnaires. The attendance rates were 88%, 88%, and 84% at the 
three rounds of health examinations, respectively.84-86  
 
8.1.2 The 40 Years Cohort 
This survey was carried out between 1985 and 1999 and included about 420,000 Norwegian 
men and women from all 19 counties of Norway. Mostly men and women aged 40-42 years 
were invited, though individuals aged 65-67 years were invited in some of the counties in the 
first of four phases of this study. The participation rate overall was 69%.87, 88 The 40 Years 
Cohort constitutes the largest cohort in the present analysis. 
 
8.1.3  Cohort of Norway – CONOR  
In this survey, regional data from 10 epidemiological surveys conducted between 1994 and 
2003 were merged into a national database. Standardized protocols, procedures and 
questionnaires were used. The questions used in the CONOR study have been validated 
previously. The average response rate for the 10 epidemiological surveys included in the 
CONOR study was 56%.84, 89, 90 A further description of these 10 surveys is included in the 
appendix. 
 
8.2 Exposure information  
After receiving specified exposure variables from the primary data of each survey, we created 
a standardized database for the pooled analysis. The smoking questions were similar, but not 
identical, across all surveys, and asked about current and former active daily smoking habits, 
smoking duration, and average number of cigarettes smoked per day. In some surveys, former 
smokers were asked about time since smoking cessation. Only the CONOR study asked about 
age at smoking initiation. In the other surveys we calculated this variable for both current (age 
at enrollment minus duration of smoking in years) and former (age at enrollment minus years 
since quitting and duration of smoking) smokers. We further categorized ever smokers 
according to the following factors: age at smoking initiation, numbers of cigarettes smoked 
per day, smoking duration in years, and number of pack-years (i.e., number of cigarettes 
smoked per day, divided by 20, multiplied by the number of years smoked). For parous 
women, the variable “smoking duration before first childbirth” was calculated in years as age 





Participants that were neither current nor former smokers were classified as never smokers, 
and current and former smokers were classified as ever smokers. A very limited number of 
women who reported they were pipe smokers were included as cigarette smokers. 
 
The CONOR files were used as a reference when merging the information from all the 
surveys into one dataset. We found common formats for variables such as age at menopause, 
age at menarche, oral contraceptive use, hormone replacement therapy use, and alcohol 
consumption, which were available only in phases III and IV of the 40 Years Survey, and in 
the CONOR study. Due to a large number of missing values for these variables in the final 
cohort, they could not be used to adjust the models in the main analysis. The proportion of 
missing values reached more than 50% either due to the fact that information was not 
collected, or that there was no answer from the participants in the questionnaires. 
 
Information about physical activity was obtained using a self-reported measure. The subjects 
were categorized into three groups based on the level of physical activity reported at the time 
of enrollment: sedentary (reading, watching television and sedentary activity), moderate 
(walking, bicycling and/or similar activities ≥4 hours per week) and heavy (light sports or 
heavy gardening ≥4 hours per week, heavy exercise or daily competitive sports).  
 
Information on number of children and age at first childbirth was obtained through linkages to 
Statistics Norway. 
 
Level of education is a proxy for socioeconomic status.56, 91 The most recent information on 
education in Statistics Norway represents the number of completed years of education, and 
was used instead of the self-reported information in the questionnaires. We used the number 
of completed years of education recorded in 1990 or 1980, and if this information was 
missing, we used that from 1970. Women were assigned to one of three categories according 
to duration of education: low (<10 years), moderate (10-12 years), high (>12 years). In 
Norway, compulsory school attendance changed from 7 to 9 years in 1965, therefore, <10 
years of education means primary school with at most 2 years of additional education. 
Similarly, women with 10-12 years of education have completed secondary school or at most 
5 years of professional training. Education lasting >12 years corresponds to university level 







In Papers I and II, a subanalysis was performed to assess the importance of alcohol 
consumption. We compared the results from the full cohort (with and without information on 
alcohol consumption) with the results from the subcohort with information on alcohol 
consumption. We used the Wald chi-square test for heterogeneity to compare HRs.92 The 
results of our sensitivity analysis should be interpreted with caution, as the subcohort with 
alcohol consumption information constitutes only 38% of women from the full cohort, and 
had only 24% of the follow-up time as compared with the full cohort. Our results suggested 
that the importance of alcohol consumption in these studies is limited. Information on alcohol 
consumption was not used for any analysis in Paper III.  
 
Please refer to section 10.3 for further discussion on alcohol consumption. 
 
8.3 Follow-up and endpoints 
Participants were followed through linkages to the Cancer Registry of Norway and the Central 
Population Register, using the unique 11-digit personal identification number, to identify all 
breast cancer cases, breast cancer deaths, emigrations and other deaths. These national 
registries are both accurate and virtually complete.93 Individuals with preexisting cancers at 
enrollment were excluded from the study sample. Furthermore, to limit the chance of 
including individuals with cancer at baseline (reverse causation), we set the date of inclusion 
to January 1 the year after the baseline questionnaire was completed. By doing so, any 
individuals with existing cancers that had not yet been diagnosed at baseline (preexisting 
condition), but were registered in the Cancer Registry of Norway later that year, would have 
been excluded from study. All prevalent cancer cases (n=7138), women without information 
on smoking status (n=2808), level of education (n=6913), body mass index (BMI) (n=2478) 
and level of physical activity (n=4207) were excluded, leaving 302,865 women included in 
the final analytical cohort. 
 
Person-years were calculated from the start of follow-up to the date of breast cancer diagnosis 
(Paper I and III), death from breast cancer (Paper II), the date of any other incident cancer 
diagnosis (except basal cell carcinoma), emigration, death from all other causes, or end of 
follow-up (31 December 2007), whichever occurred first. Breast cancer cases were classified 





cancer as the underlying cause of death according to the International Classification of 
Diseases, Revision 9 or 10. In Norway, to correct for errors and mistaken conclusions drawn 
by the physician, rules from the World Health Organization are used to ensure that the correct 
classification of cause of death is recorded on the death certificate.94, 95  
 
8.4 Statistical analysis  
All analysis were done in STATA version 12.0 (StataCorp, College Station, TX, USA) and 
SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). Differences between groups were 
analyzed with the Student’s t-test. The Wald chi-square test for heterogeneity was used to 
assume the statistical differences between HRs, whereas a p value of less than 0.05 indicated a 
significant difference between the tested HRs.92, 96 Descriptive characteristics of the study 
population in each paper were presented as means with standard deviations or frequencies 
(%), or medians with interquartile ranges when a normal distribution was not expected. The 
Cox proportional hazards model, with age as the underlying time scale, was used to 
investigate the relationship between survival time (time from start of study to censoring or 
breast cancer diagnosis or mortality), and the independent variables included in the 
multivariate models to estimate HRs with 95% CIs for the associations between different 
measures of smoking exposure and outcome. The proportionality assumption was tested by 
the link test and assumed acceptable for all the analyses presented. Tests for linear trends 
were carried out by creating an ordinal exposure variable with equally spaced scores and 
including it in the models. All regression models require complete datasets, and women with 
missing information for one or more variables were excluded from the Cox model. Hence, all 
women in the analytical cohort had complete information on the covariates included in the 
multivariate analysis. 
 
The confounders included in the multivariate models, decided a priori,97 were age at 
enrollment, number of children, age at first childbirth, BMI, level of physical activity 
(sedentary, moderate, heavy) (Paper III), and years of education (<10, 10-12, ≥13) (Papers I 
and II). We analyzed the age and multivariate-adjusted HRs with 95% CIs according to the 
selected covariates included in the multivariate analyses.  
 
We were not able to adjust for other putative confounding variables due to missing data in all, 





36% of the study sample, and thus was not included in the main multivariate analysis. To 
study the possible impact of menopausal status and breast cancer, we conducted a subanalysis 
among pre- and postmenopausal women separately (Paper I), with age 50 years used as a 
proxy for menopause in women without this information.98 Therefore, we stratified the 
analysis on smoking exposure according to attained age less than 50 years and 50 years and 
older.99 For this analysis, classification of women was based on age at breast cancer diagnosis, 
considering women premenopausal until age 50, and postmenopausal after age 50. Women 
who were premenopausal at baseline contributed to the premenopausal group for the period 
between enrollment and age 50, and to the postmenopausal group from age 51 until the end of 
follow-up. As described under “statistical analysis” in Paper I, this analysis did not reveal any 
substantial differences in the multivariate results.  
In Paper III, we stratified by age at breast cancer diagnosis (≤50>) to assess differences in pre- 
and postmenopausal breast cancer (results not displayed). 
The impact of menopausal status has been shown to be limited in most,18, 19, 26, 75 but not all,39 
previous studies for this association. 
 
8.5 Ethical aspects 
All participants recruited as from 1994 gave written informed consent to participate in the 
surveys; before 1994 returning the completed questionnaire was considered sufficient as 
acceptance to participate. Our study was approved by the National Data Inspection Board, the 
Regional Committee for Medical Research Ethics (REK), and the Norwegian Directorate of 
Health. The data were handled in accordance with the permissions given by the above-listed 
government bodies. The data were used and published in a way that none of the participants 
can be recognized. 
9 Results – summary of papers 
9.1 Paper I - Smoking duration before first childbirth: an emerging risk 
factor for breast cancer? Results from 302,865 Norwegian women 
In this paper we studied the association between smoking and breast cancer incidence. The 
main analysis was done with ever smokers as the exposure group and never smokers as the 
reference group. The different covariates for breast cancer risk were investigated and the 





level of education and alcohol consumption, and an inverse association between breast cancer 
and number of children, early age at first childbirth, BMI, and level of physical activity. The 
multivariate-adjusted results showed an increased risk of breast cancer of 15% for ever 
smokers (HR=1.15, 95% CI 1.10-1.21), 17% for former smokers (HR=1.17, 95% CI 1.10-
1.24) and 14% for current smokers (HR=1.14, 95% CI 1.08-1.20). Increased risk was also 
found for the following measures of smoking exposure: smoking duration, number of 
cigarettes smoked per day, pack-years, and age at smoking initiation (all p values <0.001). For 
smoking initiation before first childbirth, we found consistent results in favor of an increased 
risk of breast cancer with increasing smoking duration before first childbirth (p<0.001). Those 
initiating smoking after first childbirth had a reduced risk (HR=0.93, 95% CI 0.86-1.02), and 
those who smoked more than 11 years before their first childbirth had a 60% increased risk 
(HR=1.60, 95% CI 1.42-1.80) when compared with never smokers. 
 
9.2 Paper II - The association between lifetime smoking exposure and 
breast cancer mortality – results from a Norwegian Cohort 
This paper studied the association between smoking before breast cancer diagnosis and breast 
cancer mortality. Our aim was to assess if the positive associations found for smoking and 
breast cancer incidence in Paper I, also could be found for smoking and breast cancer 
mortality in the same cohort.  
 
The main analysis in this paper was done with ever smokers as the exposure group and never 
smokers as the reference group. The results showed a significantly increased risk of breast 
cancer mortality for ever (HR=1.15, 95% CI 1.02-1.30), and current (HR=1.15, 95% CI 1.02-
1.32) smokers. For former smokers a non-significant 14% increase was observed (HR=1.14, 
95% CI 0.97-1.34). A significantly increased risk was found among women who initiated 
smoking at 25 years of age of younger (HR=1.31, 95% CI 1.08-1.59), among those smoking 
for 11-20 years (HR=1.20, 95% CI 1.03-1.40), and among those smoking 11 or more 
cigarettes per day (HR=1.25, 95% CI 1.06-1.46). Parous women who initiated smoking 7 
years or more before their first childbirth had a 24% (HR=1.24, 95% CI 0.98-1.58) non-
significantly increased risk of breast cancer mortality compared to never smokers. The overall 
results revealed no dose-response relationships for any of the different measures of smoking 





number of pack-years, and smoking duration before first childbirth, all p for trends ≥0.05) and 
breast cancer mortality. 
 
9.3 Paper III - Social inequalities and smoking-associated breast cancer – 
results from a prospective cohort study 
The aim of this paper was to investigate how smoking-associated breast cancer varies by 
socioeconomic status (SES). We used level of education as a well-established measure of 
SES. The participants were stratified into three levels of education (low, moderate, high), and 
further stratified by birth cohorts (year born ≤1950>). When using low level of education as 
reference, we found that breast cancer risk increases with increasing years of education, 
overall and stratified by birth cohort (all p for trends <0.01). For women born ≤1950, those 
with a higher education had a 62% increased breast cancer risk (HR=1.62, 95% CI 1.48-1.76) 
as compared with those with a low level of education. For women born >1950, the increased 
risk was 18% (HR=1.18, 95% CI 1.04-1.34). 
 
Furthermore, we used never smokers as reference, and detected a 40% (HR=1.40, 95% CI 
1.25-1.57) higher breast cancer risk for ever as compared to never smokers, a 14% (HR=1.14, 
95% CI 1.05-1.24) higher risk for those with moderate education and a non-significant 10% 
higher risk for those with high education (HR=1.10, 95% CI 0.96-1.25) among women born 
≤1950. No increase in smoking-associated risk was found among women born after 1950 for 
any level of education. Women with a high level of education did not have a significantly 
increased risk in any of the two birth cohorts when ever smokers were compared with never 
smokers. 
  
For women with low level of education, a significant test for trend was revealed for all five 
(age at smoking initiation, smoking duration , number of cigarettes smoked per day, number 
of pack years and duration of smoking in relationship to first childbirth) measures of smoking 
exposure displayed in the table (all p values < 0.03).Compared with parous never smokers, 
women who had smoked 7 or more years before their first childbirth had a significantly 
increased risk of breast cancer for all three [low (HR=1.70, 95% CI 1.40-2.08); moderate 
(HR=1.38, 95% CI 1.24-1.55) and  high (HR=1.37, 95% CI 1.17-1.60)] level of education. 
Longer duration of smoking before first childbirth were associated with increasing risk of 







10 Discussion of methods 
10.1 Validity (external and internal) 
Validity is an expression of the degree to which a test is capable of measuring what it is 
intended to measure100 and is often separated into two components: internal validity and 
external validity. External validity, or generalizability, is the extent to which the result of a 
study is applicable to different populations in other places and at different time periods.80, 100  
Our study sample is large and the included surveys all have well validated individual datasets. 
In general, it may be difficult to generalize study results to wider populations, but we assume 
that our study conclusions can be generalized to the Caucasian and Western population.  
 
Internal validity is the degree to which the results of an observation are correct for the 
particular group of people studied. Various types of bias, or systematic errors, can detract 
from internal validity. Bias is defined as results that differ in a systematic manner from the 
true values.100 Bias concerns systematic errors, not random variation (lack of precision).  
 
10.1.1 Selection bias 
Selection bias occurs when there is a systematic difference between the characteristics of the 
people selected for a study and the characteristics of those who are not selected.100 Selection 
bias is generally less probable in prospective cohort studies than in other epidemiological 
study designs, as the outcome is not known at the time of enrollment.101 In the present pooled 
cohort, all the participants were randomly selected based on age and/or county, and represent 
a selection of the Norwegian population, both rural and urban. The participation rate was 
higher in the earliest surveys, ranging from 88% in the Norwegian Counties Study to 56% in 
the CONOR study. There is no available information on non-responders in our surveys, but 
we do not assume that they represent a skewed selection from the main cohort. Indeed, a low 
participation rate does not always indicate selection bias.102 Previous reports showed that 
individuals who choose to participate in research studies have either a high or very low level 
of education,103 but recent studies have found an increasing over-representation of highly 





in women with a high level of education; therefore a low attendance rate may have influenced 
the risk estimates in our study, representing selection bias. 
Loss to follow-up, or to exclusion prior to study enrollment, may have biased our results if the 
lost women differ from the study sample in respect to both the exposure and the outcome 
variables.  
 
10.1.2 Recall bias 
In prospective cohort studies, recall bias is of limited importance as information is collected at 
study enrollment. Most previous studies performed on the association between smoking and 
breast cancer had a case-control design, which may be subject to recall bias, a particular 
concern in studies of smoking exposure.105 
 
10.1.3 Information bias and misclassification (measurement bias) 
Measurement bias occurs when the individual measurements or classifications of disease or 
exposure are systematically inaccurate, i.e., they do not measure correctly what they are 
supposed to measure.100 Information bias can be classified as differential (dependent on the 
outcome variable) or non-differential (not dependent on the outcome variable). Information 
bias in cohort studies tends to be non-differential (not affecting any groups more than others), 
which might dilute or underestimate the effect estimates. Standard protocols were used in the 
included surveys to minimize such errors. 
 
10.1.4 Validity of outcome assessment: breast cancer incidence and mortality 
The surveys included in this pooled cohort have been previously validated.84, 85, 87, 89, 90 The 
outcomes of interest were breast cancer incidence (Papers I and III) and breast cancer 
mortality (Paper II). In a cohort study, information about endpoints should be obtained in the 
same manner, regardless of the exposure.106  
 
Reporting to the Cancer Registry of Norway is mandatory for all primary cancers diagnosed 
by a physician based on clinical evidence, or by a pathologist based on the histological report. 
The Cancer Registry of Norway is regarded as one of the most complete in the world; in 
evaluations it has shown a high degree of comparability, accuracy and timeliness, with 






Information about cause of death in Norway is reported by the physician completing the 
Cause of Death certificate, based on his/her clinical evaluation, previous knowledge of the 
deceased, previous radiologic examinations, and other relevant information. Lack of 
experience, lack of time, and lack of knowledge about the patient may lead to erroneous 
conclusions.107 As previously mentioned, to correct for errors and mistaken conclusions 
drawn by the physician, rules from the World Health Organization are used in Norway to 
ensure that the correct classification of cause of death is recorded on the death certificate.94, 95 
If an autopsy is not performed to evaluate the cause of death, the physician’s evaluation is 
reported to the official registry. Autopsy was, and perhaps is, the gold standard of diagnostics, 
but radiological, and other similar evaluations not previously available now provide novel 
diagnostic tools that can be used while the patient is still alive.107 Hence autopsy may not be 
as necessary as it once was to determine cause of death.  
A Norwegian report from 2012 compared the underlying cause of death in death certificates 
with the results from all medical autopsies (n=1773) in 2005.94 The report revealed a change 
in the underlying cause of death in 61% of the cases, and a change in the International 
Classification of Diseases code assigned (major change) in 32% of the reports, illustrating a 
considerable uncertainty when cause of death is taken from death certificates only. Overall, 
the validity of the mortality data from the Norwegian Death Registry should be regarded with 
some reservation.  
 
10.1.5 Validity of measures of smoking exposure  
Smoking exposure in these the papers was defined as active current (i.e., daily), or former 
smoking at study enrollment. Smoking duration among current smokers refers to duration 
between initiation and study enrollment. Passive and occasional smoking was not assessed as 
no data was available; therefore passive and occasional smokers were included in the 
reference group (among never smokers). Norwegian occasional smokers often define 
themselves as non-smokers.108  
The study by Dossus and colleagues demonstrated that excluding passive smokers from the 
reference group can increase the risk estimates between smoking and the outcome under 
investigation.25 Exclusion of passive smokers from the reference group was also done by 





In our cohorts, smoking information was self-reported in the baseline questionnaires, which 
avoids some bias in the ascertainment of exposure. Indeed, smoking exposure has been 
considered to be reported accurately by participants of similar studies.104, 109 Furthermore, 
selection bias could be caused by a “healthy volunteers effect”, as volunteers are often 
characterized as healthier than the general population.110 Smokers may adopt health behaviors 
when participating in health studies, making it more difficult to detect associations. Our 
pooled cohort has a high number of ever smokers, reducing the concern that a large number of 
smokers did not attend the surveys. 
 
To increase the accuracy of measures of smoking exposure in our study, differences in 
smoking behavior should have been measured throughout follow-up, instead of only at 
baseline. A report from the Million Women Study showed that among 20% of current 
smokers at baseline, 23% had quit smoking after 3 years, and 44% had quit smoking after 8 
years of follow-up.52 Also, being diagnosed with breast cancer may lead to a change in 
smoking habits; the report from the Nurses’ Health Study showed that 38% of current 
smokers quit smoking and only 2% of former smokers started smoking again after breast 
cancer diagnosis.24 To account for the missing follow-up data on smoking behavior, measures 
of smoking exposure were used in the present thesis, and ever smokers and never smokers 
were compared, using never smokers as the reference group in the main exposure analysis. 
Women who reported being a current or former smoker were classified as ever smokers. As 
most women in Norway initiate smoking before age 25,12 we consider it unlikely that a 
significant number of women who reported they were never smokers at study enrollment 
(mean age at study enrollment 41 years) started smoking during follow-up; those classified as 
never smokers would likely have remained never smokers. Classification (measurement) bias 
was therefore reduced significantly by using ever and never smokers as the main exposure 
categories in our study, as we lack follow-up data.  
 
The use of ever smokers in the analysis, instead of current and former smokers, makes it 
impossible to distinguish current smoking, which is often used as a surrogate for heavy 
smoking exposure,111 and former smoking, often with a disparate smoking exposure history. 
Theoretically, using ever instead of current smokers in these analyses may have reduced the 






In Paper II, our results using high number of pack-years as a proxy for lifetime smoking 
exposure are discussed. In our pooled cohort we found a mean exposure of 13 pack-years for 
current smokers, which was far less than in the study by Pierce and colleagues, which found a 
mean exposure among current smokers of 39 pack-years. Pierce and colleagues did the 
smoking assessment 2 years after breast cancer diagnosis, whereas our study did it at study 
enrollment before breast cancer diagnosis. Hence, selection bias in favor of long-term 
smokers and recall bias with respect to remembering smoking history may explain the very 
high mean exposure in the Pierce study. Also, mean age at enrollment in the Pierce study was 
60, as compared with 44 years in our pooled cohort, which could explain why our current 
smokers had a shorter smoking duration than those reported other studies.25, 26 As discussed in 




In a study of the association between an exposure and the occurrence of a disease, 
confounding can occur when another exposure exists in the study population that is associated 
both with the disease and the exposure being examined. A high number of included 
individuals in a cohort study increase the chance of obtaining significant p values. At the 
same time, control of confounders may be extensively difficult in large studies, thus 
threatening study validity, which is not displayed through the p value.100 In contrast to bias, it 
is possible to control for confounders by stratification and adjustment in multivariate models. 
Comparison between unadjusted and adjusted associations is the best evidence to support the 
presence of confounding if the estimates differ.63 In the multivariate models of the papers in 
this thesis, parity, age at first childbirth, smoking duration, and BMI (and a subanalysis on 
alcohol consumption in Papers I and II) were included in an attempt to exclude the possibility 
that these factors confounded our results for smoking and breast cancer.  
 
In Paper I, our Table 4 displays both age-adjusted and multivariate-adjusted risk estimates. In 
Papers II and III, we chose not to display both results as they were materially similar, 
indicating that the confounders included in the multivariate analysis were of minor 
importance in these papers. Age-analyses were also done for all the analyses in paper III, but 







10.2.1 Residual confounding 
Bias that remains after adjustment is an example of residual confounding.80 The findings of 
the papers included in this thesis may be the result of residual confounding in the following 
ways: 
• We found an increased risk among women who start to smoke early in life. 
This may be confounded by smoking duration as women who start to smoke 
early also tend to smoke for a longer duration. 
• Women who start smoking before their first childbirth may also have their first 
childbirth later in life, which also increases breast cancer risk. In addition, 
late first childbirth increases the risk of smoking initiation before first 
childbirth. 
• Any difference in breast cancer risk before or after menopause may be 
confounded by BMI as there is an increased risk of breast cancer among 
premenopausal women with high BMI, and smokers generally have a lower 
BMI (opposing effect). Conversely, an increased risk of breast cancer among 
thin women before menopause may due to the face that leaner women tend to 
smoke more. 
• Passive smokers were included in the reference group as never smokers, which 
may have diluted our results for the association between smoking and breast 
cancer. Cohort studies have been shown to underestimate the effect of smoking 
if passive smokers are included in the reference group, but some studies that 
were able to exclude passive smokers from the reference group did not show 
an increased risk.18, 112 Moreover, the exclusion of passive smokers from the 
reference group19, 39 (never active, never passive) could make the outcome 
difficult to compare with studies that do include passive smokers in the 
reference group. 
 
 (A biologic rationale for a genetic difference in breast cancer risk between active and passive 
smokers was presented in 2000 by Morabia and colleagues, and will not be discussed further 






10.3 Alcohol consumption 
The confounding effect between alcohol consumption and breast cancer risk has been widely 
discussed.19, 25, 114 The rationale for this is that heavy smokers report more alcohol 
consumption than never smokers, and when studying the effects of smoking, there is concern 
as to whether the carcinogenic effect comes from alcohol instead of smoking. The validity of 
self-reported alcohol consumption has been questioned, and is expected to be underreported in 
most cases, which may cause residual confounding.105, 115 Alcohol consumption may be a 
greater problem among current than former smokers, as current smokers drink more than 
former smokers.2, 18  
 
A large meta-analysis published in 2002 by Hamajiima and colleagues114 included 53 
epidemiological studies and reported that alcohol consumption could fully explain the 
increased breast cancer risk among smokers, and hence that alcohol, not smoking, was 
responsible for the increased risk of breast cancer reported in that study. This study is widely 
cited as it is large and well performed, but had a rather short follow-up period, used 
ever/never as the measure of smoking, and did not exclude passive smokers from the 
reference group.116 However, it stands as one of the most important reports of this association.  
There is convincing evidence of a positive association between alcohol consumption and 
breast cancer,117-120 and there seems to be a linear dose-response association, as each 10 grams 
of alcohol consumed per day increases the risk by between 7.1%114 and 10%.119 Given this 
association, and the results from Hamajiima and colleagues, it is difficult to disregard the 
potential influence of alcohol consumption on the association between active smoking and 
breast cancer.  
At least 11 prospective cohort studies on smoking before first childbirth and breast cancer, all 
of which adjusted for alcohol consumption, found an increased risk, mostly with a dose-
response association.18-20, 22-26, 39, 75 Some argue that this association should be measured only 
among never drinkers, to exclude the chance of bias from alcohol. In the paper by Dossus and 
colleagues, a positive association between smoking and breast cancer was found only among 
non-drinkers, but this study did not include information on the amount of alcohol consumed, 
and did not report whether any dose-response was present.25 Rosenberg and colleagues found 
a positive association between smoking and breast cancer risk after controlling for smoking 






Information on alcohol consumption in our study was categorized according to weekly 
consumption (<weekly, weekly, >weekly), not total consumption (i.e., grams per week), as 
weekly consumption was available for more study participants. Grams per week may give a 
better estimation of total alcohol consumption, especially if the drinking pattern is dominated 
by high consumption on weekends (“binge drinking”). In our subanalysis on alcohol 
consumption we found materially the same results as in the full pooled cohort (Papers I and 
II). Smoking is particularly prevalent among heavy drinkers and much less common among 
abstainers.116, 121 Consumption of alcohol seems to follow social gradients; a high level of 
education and income increases alcohol consumption.116 The lack of alcohol information in 
Paper III may cause confounding, both with smoking exposure and level of education, which 
is a major limitation of this paper. 
It is still debated whether alcohol is a confounder of the association between smoking and 
breast cancer. Alcohol consumption should most likely be considered in relation to duration 
of drinking and amount consumed, and maybe in relation to the period of life in which alcohol 
was consumed. No studies to-date have successfully adjusted for alcohol consumption before 
first childbirth when assessing smoking exposure before first childbirth and breast cancer. The 
recent study by Liu and colleagues found that alcohol consumption before first childbirth was 
dose-dependently associated with breast cancer, independent of drinking after first 
pregnancy.122 More studies should be conducted on the importance of alcohol consumption, 
and probably other known carcinogens, in the time window between menarche and first 
childbirth, as alcohol consumption among adolescents in Norway is increasing: 10% of all 15-
year-olds now drink alcohol at least once a week.123  
Although it is questionable whether alcohol consumption is a confounder for the association 
between smoking and breast cancer, we consider the missing information on alcohol 
consumption a main limitation of the papers included in this thesis. 
 
10.4 Mammography screening 
Mammography screening for breast cancer was not common in Norway during the first 20 
years of follow-up in our study. The Norwegian Breast Cancer Screening Program includes 
women aged 50 to 69 years. It started at the end of 1995 and became a nationwide program in 
2005,124 just 2 years before the end of our follow-up period. Therefore it seems unlikely that 





The 2014 report from the Behavioral Risk Factor Surveillance System in the United States 
indicated that participation in mammography screening is substantially lower among current 
smokers compared to non-smokers.125 This was also found in previous studies.126 A lower 
participation among smokers may have decreased the number of cases detected among current 
smokers, possibly leading to an underestimation of the association between smoking and 
breast cancer among current smokers. Also, lower mammography screening participation 
among current smokers may lead to an overestimation of the association between smoking 
and breast cancer mortality among current smokers, as compared with former and never 
smokers, due to the possibility that breast cancer is not detected in time. 
 
10.5 Validity of variables for level of education 
To classify each participant according to level of education, we used the most recent 
information regarding duration of education obtained from Statistics Norway to assign 
participants to one of three categories: low (<10 years), moderate (10-12 years), and high 
(>12 years). In1965, duration of compulsory school attendance in Norway changed from 7 to 
9 years, therefore, <10 years of education means primary school with at most 2 years of 
additional education. Similarly, women with 10-12 years of education have completed 
secondary school, or at most 5 years of professional training. Education lasting >12 years 
corresponds to university level education, or a lower level of education with several years of 
professional training.  
 
Information on education in Statistics Norway comes from four population censuses 
conducted in 1970, 1980, and 1990 (each census year is November 1st).129, 130 In the 1970 
census (as in the census of 1960) education was coded according to information from personal 
visits to each household. In the 1980 and 1990 censuses, register data for highest duration of 
education was used to determine level of education. From the 1970 census onwards, education 
was coded according to the Norwegian Standard Classification of Education, which is 
compatible with the International Standard Classification of Education.131  
 
Higher education is associated with increased breast cancer risk. As demonstrated by Braaten 
and colleagues (2004), the increased risk conferred by education can be explained by known 
risk factors such as lower parity, higher age at first childbirth, BMI, use of oral contraceptives 






reproductive factors and anthropometrics are used in the model, it is redundant to keep level 
of education as a covariate in the model.56 As an established risk factor for breast cancer, level 
of education was discussed and included as an adjusting variable in the main model of 
seven20, 23, 25-27, 39, 76 of the most recent cohort studies on the association between active 
smoking and breast cancer. Our pooled cohort also comprised information on income, but it 
was problematic to use this information in a longitudinal study, as it is difficult to compare 
income levels across groups recruited at different time periods.  
 
10.6 Time variable in the model 
We used the semiparametric Cox proportional Hazards model132 to find our risk estimates. 
The time-independent model was used with age (at enrollment) as the time scale. In the Cox 
model, the assumption underlying the model was that the risk factor is associated with the 
fixed relative increase in the instantaneous risk of the outcome of interest, compared with the 
reference hazard63 i.e. the hazard among those exposed is constant at any given point in time 
(Figure 8A).  
 
Figure 8: Hazard over time in two hypothetical situations. From Szklo/Nieto: p 266. Reprinted with permission.63 
 
As our study had a long follow-up period, the hazard will fluctuate with time (“calendar 
effect”) due to changes in treatment protocols, mammography screening programs, use of 
hormone replacement therapy at certain time periods, or similar, as illustrated in Figure 8B. 
To account for some of these changes, stratification by birth cohort is recommended133 and 
was performed in all papers in this thesis. Using other “time-dependent” time scales such as 






One problem of using age as the time scale (underlying time variable) is that the three 
included surveys were conducted decades apart, and the model considers a woman who was 
40 years of age at inclusion in 1975 in exactly the same manner as a women who was 40 years 
of age at inclusion in 1995, though they were included 20 years apart. A model using calendar 
year of birth would have accounted for this possible bias. However, when stratifying by birth 
cohort, our model with age should have accounted sufficiently for this problem. 
 
The use of a time model consistent with the data is important, but it may not always make a 
large difference.134 We conclude that, despite some downsides, the use of age (at enrollment) 
as the time variable for this longitudinal study is the most appropriate. 
 
11 Discussion of main results  
 
The main findings are discussed in the respective papers (Papers I-III). The discussion below 
is focused on the main messages of the three papers. 
11.1 Paper I 
In this paper we found that current, former, and ever smoking was associated with breast 
cancer incidence. By showing statistically significant dose-response associations with 
smoking exposures, and duration of smoking before first childbirth, this paper adds more 
epidemiological evidence to the notion that there is an association between smoking and 
breast cancer, with excellent power. 
 
A dose-response relationship is regarded as strong evidence that a cause-effect relationship 
exists.63 Our observation is reflected in other recent studies on smoking and breast cancer 
incidence. Gaudet and colleagues26 found a similar risk increase of 45% for women who 
smoked 11 years or more before their first childbirth. The study from the United States Black 
Women’s Cohort by Rosenberg and colleagues39 found a doubling in risk for premenopausal 
breast cancer among those with a history of more than 20 pack-years, and smoking more than 
5 years before their first childbirth. No association was found for postmenopausal breast 
cancer in this study. Also, the study by Dossus and colleagues25 from the European 
Prospective Investigation into Nutrition and Cancer (EPIC) found a 73% risk increase 





found the highest risks among women without a family history of breast cancer, or late 
menarche.  
 
More than 150 studies have been performed on the association between smoking and breast 
cancer. Regardless, this issue is still under debate. A majority of studies now conclude that 
there is a consistent, albeit weak, increase in risk for current smokes, and that the risk seems 
to increase with increasing smoking exposure. Ideal study designs, such as intervention 
studies or randomized controlled trials, are not possible, and the perfect epidemiological 
cohort study for this association is difficult to conduct. This study adds information on the 
association between smoking and breast cancer, and supports the notion that smoking before 
first childbirth is a risk factor for breast cancer. 
 
11.2 Paper II 
As smoking arises as a risk factor for breast cancer, the need for more studies in relation to 
this association emerges. Paper II showed that lifetime smoking exposure was significantly 
associated with the risk of breast cancer mortality among ever smokers compared with never 
smokers, but without clear dose-response associations. Since the association between smoking 
and breast cancer is not strong, high risk estimates for smoking and breast cancer mortality 
was not expected. Two recent studies that assessed smoking exposure before breast cancer 
diagnosis have been published; one by Saquib and colleagues,135 and one by Pierce and 
colleagues.111 In both of these papers, the assessment of current smoking at diagnosis did not 
reveal any risk increase for breast cancer. When reanalyzing the same data according to 
smoking intensity and duration before diagnosis, a different conclusion was reached, with a 
54% increased risk of dying from breast cancer (HR=1.54, 95% CI 1.07-2.32) reported in the 
Saquib paper. Similarly, a 54% increased risk (HR=1.54, 95% CI 1.24-1.91) was found in the 
Pierce paper among former smokers who smoked more than 35 pack-years. 
 
However, when comparing these results with the results from Paper II, there is a concern 
regarding selection bias in the studies by Saquib and colleagues and Pierce and colleagues. 
The cohort in the Saquib paper had less than 5% current smokers, and among those, one-third 
had a smoking exposure of more than 20 pack-years. Similarly, the current smokers in the 
Pierce paper had a mean smoking exposure of 39 pack-years. Analysis for this high exposure 





more than 20 pack-years. Our results for 11 pack-years or more rendered a non-significant 
21% risk increase (HR=1.21, 95% CI 0.66-2.23) for breast cancer mortality.  
Our use of ever smokers in the analysis instead of current and former smokers made it 
impossible to distinguish between current smoking, which is often used as a surrogate for 
heavy smoking exposure, and former smoking, often with a disparate history of smoking 
exposure. It is possible that the use of current instead of ever smokers could have revealed 
stronger risk estimates. 
 
“Competing risk” occurs when another event takes place among participants that is different 
from the disease under observation. The possibility of dying from smoking-associated 
diseases other than breast cancer during follow-up, such as cardiovascular disease, lung 
cancer, or chronic obstructive pulmonary disease, is a concern in mortality studies. Removing 
competing risks by statistical maneuvers without altering the mortality estimates for breast 
cancer is difficult.80, 136 Our dataset lacks information on causes of death other than breast 
cancer, ovarian cancer, and colorectal cancer, which makes any proper estimate of competing 
risks difficult. Competing risks therefore remains as a major limitation of Paper II. 
 
Further prospective cohort studies should be performed, possibly in cohorts with very high 
smoking exposure, in order to draw solid conclusions on the association between of smoking 
exposure and breast cancer mortality. In paper II we found that using ever smoking as a 
measure of lifetime smoking exposure conferred a significantly increased risk of breast cancer 
mortality compared with never smokers, but our results were difficult with the recent papers 
due to the lack of participants with very high smoking exposure.   
 
11.3 Paper III 
Significant associations were found for ever, current and former smoking and breast cancer 
incidence in Paper I, making this cohort suitable for a more detailed approach of the 
socioeconomic implications of this association. The social gradient in many diseases are well 
known, but varies between cancer sites. For breast cancer, the association with higher SES is 
reported for income, occupation or socioeconomic group, and for level of education.55, 56, 137, 
138 In this paper, we used level of education, a well-established measure of SES.91, 139 
We confirmed the elevated breast cancer risk with higher educational achievement, as 





observation of a non-significant risk increase for smoking-associated breast cancer in women 
with higher education in both birth cohorts shows that never and ever smokers with high level 
of education has a similar risk of breast cancer, indicating that smoking has a limited impact 
on women with higher education. Further, a significant difference is observed in the cohort 
born in and before 1950 between women with low and high level of education. This 
observation may indicate a socioeconomic gradient for smoking-associated breast cancer in 
this age group, which is difficult to explain based on our previous knowledge of a higher 
breast cancer risk among higher educated women. Smoking may have a stronger impact on 
breast cancer risk in this category of elderly women, possibly reducing the importance of 
other known breast cancer risk factors. 
 
The analyses for the different smoking exposures: age at smoking initiation, smoking 
duration, number of cigarettes smoked per day, pack-years and smoking duration before first 
childbirth, mostly showed an increasing breast cancer risk with increasing smoking exposure.  
In particular, the results for women with low level of education revealed a significant trend 
for all measures of smoking exposure. As previously discussed in the thesis, recent literature 
shows the importance of analyzing the smoking and breast cancer association with increasing 
smoking exposures, not only by smoking status (ever, current, former, never), to promote the 
importance of dose-response. The results for smoking duration before first childbirth shows 
an increasing risk with increasing duration of smoking for all levels of education, and as 
previously discussed, it supports the notion that smoking in this time period is an important 
risk factor for breast cancer. 
 
Except from the observation of an increased smoking-associated breast cancer risk among low 
and moderately educated women born in and before 1950, which is not observed among 
women with high education, our study finds limited evidence that smoking-associated breast 
cancer have an important impact on social inequalities in health.  
12 Conclusions 
12.1 Paper I 
• Active smoking increases breast cancer risk 
• The risk increases with increasing smoking exposure, i.e., longer smoking duration, 





• Smoking initiation before first childbirth increases the risk of breast cancer 
 
12.2 Paper II 
• Lifetime smoking exposure increases the risk of breast cancer mortality 
• Smoking before first childbirth do not increase the risk of breast cancer mortality 
• Dose-response associations were not revealed 
 
12.3 Paper III 
• Increasing level of education increases breast cancer risk 
• Smoking for several years before first childbirth increases breast cancer risk, 
regardless of level of education 
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QUESTIONNAIRE THREE COUNTIES  
FINNMARK COUNTY 





QUESTIONNAIRE THREE COUNTIES STUDY, 
SOGN OG FJORDANE AND OPPLAND COUNTIES,  
ROUND 1 AND 2 


QUESTIONNAIRE THREE COUNTIES STUDY, 




QUESTIONNAIRE 40 YEARS STUDY, 
ROUND 1 
 
QUESTIONNAIRE 40 YEARS STUDY, 
ROUND 2 
 
QUESTIONNAIRE 40 YEARS STUDY, 
ROUND 3 
 
















2. Do you have, or have you had?








3. Have you during the last year suffered from pain and/or
stiffness in muscles and joints that have lasted for at least 3 months ?
Yes
No
4. Have you in the last two weeks felt :









5a. How has your physical activity during leisure time been over the last year ? 
Think of your weekly average for the year. Time spent going to  or fromworkk counts as leisure time 
Hours per week                     
                                                      None     Less than 1     1-2     3 or more
Light activity
 (not sweating or out of breath )
Hard physical activity
(sweating/out of breath )
5 b.  Please note physical activity during the past year in your spare time. 
If activity varies between summer and wintertime,   
note a mean value.
(Tick one only)
Reading, watching TV or any other sedentary activity?
Walking, cycling, or other activity, other for at least 4 hours a week?
(Count also walking back and forth from work)
Light sports, heavy gardening?
(At least 4 thours perweek)
 Hard exercise, competitive sports? Regularly and several times a week
SMOKING
6 . How many hours a day do you normally spend in smoke-filled rooms? 
Write 0 if you don`t spend time in smoke-filled rooms
Number of hours………..
7. Did any of the adults smoke at home when you grew up?
Yes
No
8. Do you now, or have you ever lived together with a daily smoker after the age of 20 years?
Yes
No
9. Do you smoke ?




10. If you previously smoked daily, how long is it since you quit?
………number of years
11. If you smoke daily now or previously: 
How many cigarettes do you,or did you usually smoke per day?
Number of cigarettes…………….
12. How old were you when you began smoking?
………..year
13. How many years in all have you smoked daily ?
…………..years
COFFEE, TEA AND ALCOHOL
14.a How many cups of  coffee do you usually drink daily ?
Write 0 if you do not drink coffee daily
Boiled coffee (coarsely ground), number……
Coffee other, number………..
14.b What type of coffee do you usually drink?
Please tick
Filter/instant coffee
Boiled coffee (coarsely ground)
Other (espresso etc)
Do not drink coffee
14c. How many cups of  coffee/tea do you usually drink daily? 
Write 0 if you do not drink coffee/tea daily
Number of cups with coffee………….
Number of cups with tea…………
15 a. How many times a month do you usually drink alcohol? 
Do not count low-alcohol beer. Put 0 if less than once a month.
Number of times………….
15 b. Approximately how often during the past 12 months have you consumed alcohol?
(Do not count low-alcohol beer)
4-7 times a week   
2-3 times a week      
App. 1 time a week   
2-3 times a month
Appr. 1 time a month  
A few times last year    
Have not drunk alcohol the last year                                        
Have never drunk alcohol
16 a. How many glasses of beer, wine or spirits 
do you usually drink during a two-weeks period? 
Do not count low-alcohol beer. Put 0 if you do not drink alcohol.
Beer…..glasses   Wine…..glasses   Spirits…..glasses
For those who  have consumed alcohol during the  past year
16 b. When you drank alcohol, how many glasses
 did you usually drink ?
Number of glasses………….
16 c. Approximately how often during the past 12 months have you consumed alcohol 
corresponding to at least 5 glasses of spirits in 24 hours?
Number of times………..
16 d. When you drink alcohol, do you usually drink: (Tick one or more).
Beer                  Wine                     Spirits (hard liquor)




18 a. What is the highest level of education you have completed?
Less than 7 year of primary school
 7-10 years primary/secondary school
Technical school, middle school, vocational school, 1-2 years senior high school
High school diploma (3-4 years)
College/university, less than 4 years
College/university, 4 or more years
18 b. How many years education have you completed all together?
(Count every year you went to school)
Number of years………….
ILLNESS IN THE FAMILY
19. Have one or more of your parents or siblings had a heart attack




20. Tick for those relatives who have or have had:








Age when diabetes was first diagnosed
RESIDENLY
21. In which muncipality did you live at the age of 1 year? 
If you did not live in Norway, give country of residence instead of municipality.
………………………..






23. How large is your home?
………m2
24. Do you have wall-to-wall carpets in the living-room?
Yes          No
25. Is there a cat in your home?
Yes           No
FAMILY AND FRIENDS
26 a. With whom do you live? Tick one for each question and  write the number
                                                       Yes                  No                  Number
Spouse/Partner
Other persons older than 18 years 
Persons younger than 18 years 




                                                     Yes            No              Number
Spouse/Partner
Other persons older than 18 years
Persons younger than 18 years 
26 c (only at the questionary for the elderly) 
Where do you live ? Please tick
Home
Institution
Do you live with? 
                                   Yes            No
Spouse/Partner?
Other persones? 
27. How many of the children attend day care/kindergarten/nursery school?
………..
28. How many good friends do you have with whom you can talk confidentially
and who can provide help if you need it?
 (Do not count people you live with, but do include other relatives)
…………………….




30. How often do you usually take part in organised activities, e.g. 
sewing circles, sports clubs, political meetings, religious or other organizations?
Never, or just a few times a year
1-2 times a month (before year 1996), 1-3 times a month (after year 1996)
Approximately once a week
More than once a week
WORK
31. What is your current work situation?
Paid work
Full-time housework
Under education, military service
Unemployed, on leave without payment
32 a. How many hours of paid work do you have per week?
……………….number of hours
32 b. What is your current work situation – paid work?
Yes, full-time
Yes, part time 
No








34. Do you work shifts or nights?
Yes
 No
35. If you have paid or unpaid work, which statement describes your work best?
Mostly sedentary work? 
(e.g. office work, mounting)
Work that requires a lot of walking?
 (e.g. shop assistant, light industrial work, teaching)
Work that requires a lot of walking and lifting?
 (e.g. postman, nursing, construction)
Heavy manual labour? (e.g. forestry, heavy farmwork, heavy construction )




Yes, my own decision
37 a. Do you have any of the following occupations ? 
(full time or part time) Tick one for each question




37 b. What occupation/title did you have at this work? 
(the question refers to another question (not CONOR) about the occupation 
where they worked the longest period during the past year) 
Ex secretary, teacher, industrial worker, nursing, carpenter, l
eader, salesman, driver etc)
Occupation:………………………………………………
YOUR OWN ILLNESS and INJURIES
38. Have you ever had: 
Tick one for each question. State age at event. 
If it has happened several times, write age at the last event.






39. Do you have or have you ever had?
Tick yes or no for each question





Psychological problems for which you have sought help
40. Do you cough almost daily for some periods of the year?
Yes      No 
41. If yes, 
do you bring up phlegm?
Yes       No
42. If you cough almost daily for some periods of the year, have you had this 
kind of cough for as long as 3 months in each of the last two years?
Yes     No
43. How often do you suffer from sleeplessness?
Never, or just a few times a year
1-2 times a month (before year 2000), 1-3 times a month (after year 2000)
Approximately once a week
More than once a week
44. Have you in the last twelve months suffered from sleeplessness  
to the extent that it has affected your ability to work ?             Yes         No                                                                          
USE OF MEDICATION
45. Do you take? 
   Currently             Previously               Never
Lipid lowering drugs
Medications for high blood pressure
46 a. Have you for any length of time in the past year used any of the following
 medications every day or almost daily? 
Indicate how many months you have used the medication. Write 0 if you did not take the medication.
Medications:      
Painkillers             ………months.
Sleeping pills         ………months.
Tranquilizers        ………months.
Antidepressants    ………months.
Allergy pills          ………months.
Asthma medication ………months.
Only medication bought at pharmacy .
Do not include dietary supplements
 
46 b. How often during the last 4 weeks
 have you taken any of the following medication?
Tick one per line
                                                   Daily       Weekly                   Less than            Not taken






Other medication on prescription
46.c Fill in name of medication, reason for use and time used from q 46.b
Brand name           Reason for use                     For how long








47 a. Have you for any length of time in the past year taken any of the 
following daily or almost daily?
Indicate how many months you have used them. Write 0 if you did not take any.
Iron tablets                                         ………..months
Vitamin D supplements                       ………..months
Other vitamin supplements                 ………..months
Cod liver oil                                         ………..months                
47 b. Do you take any of the following?
                                        Yes, daily       Sometimes           No
Cod liver oil, capsules 
Fish oil capsules  
Vitamin and or 
mineral supplements
THE REST OF THE FORM SHOULD ONLY BE FILLED IN BY WOMEN
48. How old were you when you started menstruating?
………..year
49. If you no longer menstruate, how old were you when you stopped menstruating?
………..year
50. Are you pregnant at the moment?
Yes               No                      Unsure                     Postmenopausal
51. How many children have you given birth to?
………children
52. If you have given birth, what year was the child born and how many 
months did you breastfeed each child







53. Do you use or have you ever used:
                                                                Now         Previously        Never
Contraceptive pills (OC) (incl. minipill)
Contraceptive injections
Hormonal intrauterine device
Estrogen (tablets or patches)
Estrogen (cream or suppositories)
54. If you use contraceptive pills, hormonal intrauterine device, or estrogen, 
what brand do you currently use?
………………………………………………











Total included both 
genders
No of Surveys CONOR
The Three Counties 1974-88 Oppland, Sogn og Fjordane, Finnmark Aprx. 93000 10 incl follow-up
Follow up 2006-08 65000 (not included)
Tromsø Health Study II 1979-80 Tromsø 1 (not included)
Tromsø Health Study III 1986-87 Tromsø 1 (not included)
40 years Survey 1985-99 40-42 year old Aprx 382 000 19
I 1985-87 Østfold, Aust-Agder, Vest-Agder, Sør-Trøndelag
II 1988-94 All 19 counties
III 1994-97 12 counties
IV 1997-98 11 counties
The Nord-Trøndelag Health Study (HUNT I) 1984-86 Nord-Trøndelag 1 (not included)
CONOR 1994-2003 181891
Tromsø Health Study IV 1994-95 Tromsø 26925 1 x
The Nord-Trøndelag Health Study (HUNT II) 1995-97 Nord-Trøndelag 65018 1 x
Hordaland Health Study (HUSK) 1997-99 Hordaland 25530 1 x
Tromsø Health Study V 2001 Tromsø 8077 1
Oslo Health Study II 2001-2 Oslo 6919 1 x
Oppland and Hedmark Health Study (OPPHED) 2001-2 Oppland and Hedmark 12402 1 x
Troms and Finnmark Health Study (TROFINN)  2001-3 Troms and Finnmark 9327 1 x
Oslo Health Study (HUBRO) 2000-01 Oslo 22015 x
Oslo Immigrant Health Study (i-HUBRO) 2002 Oslo 3683 x
Romsås Study II (MoRo) 2003 Romsås (Oslo) 1995 x
Totalt 3C (89´)+ 40Y (382`) + CONOR (181`) Aprx 652 000
Studies included in the Pooled Cohort 







Men and women 
403,691 
Men and women 
137,182 




40 Years Cohort 
1985-1999 
Cohort of Norway 
1994-2003 
Excluded due to 
 
• emigrations or death prior to 
follow up (n=3933) 
• prevalent cancer (n=7138) 
 
Missing information on 
• smoking information (n=2808) 
• information of antropoimetics 
(n=2478) 
• Physical activity (n=4207) 












31. Dec 2007 1. Jan 1975 23 years observation period 
Median follow up 14 years 




NORWEGIAN HEALTH STUDIES 
 
Randi Selmer 30 Nov 2007. Updated 23 June 2008. 
Measurements in Health Surveys  1972-2003. 
 
Blood pressure 
1. 1972-84:  Systolic and diastolic blood pressure were measured twice with a standard 
mercury sphygmomanometer after 4 minutes rest. The second measurement has 
usually been used in follow up studies. The interval between first and second 
measurement was 1 minute. Diastolic blood pressure was recorded at the 
disappearance of the Korotkoff sounds (phase V). When phase V was absent, phase IV 
was used. Standard size cuffs were used throughout.  The blood pressure was 
measured on the right upper arm with the person sitting on a chair.    
2. 1985-2003: Pulse recordings, systolic and diastolic blood pressures were measured by 
an automatic device (DINAMAP, Criticon, Tampa, USA), which measured the blood 
pressure in mm Hg automatically by an oscillometric method. After 2 minutes 
preceding rest, three recordings were made at one-minute intervals. The values of the 
mean of the second and third systolic blood pressure measurements were used in 
calculating the cardiovascular risk score (CVD risk score). Arm circumference of right 
upper arm was measured 10 cm above fossa cubiti. From these measurements small, 
medium or large cuff was chosen. The blood pressure was measured on the right upper 
arm with the person sitting on a chair.    
The two methods have been compared  (PG Lund-Larsen: Blodtrykk målt med 
kvikksølvmanometer og med Dinamap under feltforhold- en sammenligning. Norsk 
epidemiologi 1997; 7 (2): 235-41)  
 
Serum analyses 
Sera from the screenings were sent to the Department of Clinical Chemistry, Ullevål 
University Hospital, Oslo, Norway 
 
Serum lipids 
Non-enzymatic methods: Total cholesterol and triglycerides 
Non enzymatic methods were used in Oslo 1972-73, first screening in Finnmark, Oppland and 
Sogn og Fjordane 1974-78 and second screening in Finnmark 1977-78. Enzymatic methods 
were used from second screening in Sogn og Fjordane 1980. 
 
Stensvold et al. BMJ 1993: 
 “A blood sample was taken from  non-fasting subjects and analysed for serum concentrations 
of total cholesterol and triglycerides, both components being measured non-enzymatically on 
a Tchnicon AutoAnalyzer. On later comparison with enzymatic methods, the non-enzymatic 
methods used gave on average 10% higher triglyceride values and 8% higher cholesterol 
values. The participants reported the time  since last meal.”  
 
The triglyceride values included in the data set are corrected values compatible with 
enzymatic methods according to the formula: 
 (New method) = 0.90 x (Old method) - 0.11 
 
The cholesterol values included in the data set are corrected values compatible with enzymatic 
methods according to the formula: 
 (New method) = 0.92 x (Old method) + 0.03 
 
The formula was evolved after extensive test program comparing new and old method. 
 
Enzymatic methods: 
All measurements of HDL cholesterol were enzymatic. (Stensvold I, Urdal P, Thürmer H, 
Tverdal A, Lund-Larsen PG, Foss OP. High-density lipoprotein cholesterol and coronary, 
cardiovascular and all cause mortality among middle-aged Norwegian men and women.Eur 
Heart J. 1992 Sep;13(9):1155-63.)    
   
Non-fasting serum total cholesterol, serum HDL cholesterol, glucose and serum triglycerides 
were measured directly by an enzymatic method (Technicon or Hitachi autoanalyzer). 
Seronorm Lipoprotein was used as internal quality control material for the lipid analyses and 
Autonorm Human Liquid for the glucose. The control material was done at the start and for 
every 30th sample.  
 
Stability of cholesterol measurements from 1972 has been documented ( OP Foss and P 
Urdal: Kolesterol gjennom mer enn 25 år: kan svarene sammenliknes over så lang tid?  Norsk 
epidemiologi 2003; 13 (1): 85-88) ) 
 
Glucose 
Serum glucose was measured in first screening in Finnmark, Oppland and Sogn og Fjordane 
1974-78 and second screening in Finnmark 1977-78 and in a sample in second screening in 
Oppland 1981-83 by a non enzymatic method by Brown ( ME Brown: Ultra-micro sugar 
determinations using 2, 9-dimethyl-1, 10-phenanthroline hydrochloride (Neocuproine). 
Diebetes 10:60, 1961.) The same method was used in  Oslo 1972-73. The results obtained 
with this method were about 0.8-1.1 mmol/l higher than the true concentration defined as the 
value found with a specific enzymatic method.  
    
From 1994 non fasting serum glucose was measured by enzymatic method described above.  
The old glucose values have not been adjusted to levels comparable with enzymatic methods.   
 
Weight and height 
Body weight (in kilograms, one decimal) and height (in centimetres, one decimal) was 
measured according to standard protocol with the participants wearing light clothing without 
shoes (manually recorded until 2000 and after that with an electronic Height and Weight 
scale)  
 
Waist and hip 
Waist and hip were measured from Finnmark and Akershus 1996/97 and onwards. Waist 
circumference was measured at the umbilicus to the nearest cm with the subject standing and 
breathing normally. In obese individuals, waist circumference was defined as the midpoint 
between the iliac crest and lower margin of ribs. Hip circumference was measured as the 
maximum circumference around the buttocks. Both waist and hip were measured with a 
measuring tape of steel – which was emphasized to be horizontal. Waist and hip 
circumference were used to calculate the waist-hip ratio using the formula waist (cm)/ hip 
circumference (cm).  
 
Measurements of lipids in three counties 1974-1988 
 Finnmark   Sogn og Fjordane Oppland  
Name       
Screening 1    
u1kol_mg 
total cholesterol 
mg/dl old method 
total cholesterol mg/dl 
old method 
total cholesterol mg/dl 
old method 
u1kolest 
total cholesterol old 
method converted to 
mmol/l by factor 
0.02586 
total cholesterol old 
method converted to 
mmol/l by factor 
0.02586 
total cholesterol old 
method converted to 




mmol/l converted to 
enzymatic values 
from u1kolest by 
formulae 
total cholesterol 
mmol/l converted to 
enzymatic values 
from u1kolest by 
formulae 
total cholesterol mmol/l 
converted to enzymatic 
values from u1kolest by 
formulae 

















from u1trigly by 
formulae 
triglycerides mmol/l 
converted to enzymatic 
values from u1trigly by 
formulae 
Screening 2    
u2kol_mg 
total cholesterol 
mg/dl old method 
total cholesterol mg/dl 
enzymatic method 
total cholesterol mg/dl 
enzymatic method 
u2kolest 
total cholesterol old 
method converted to 




converted to mmol/l 
by factor 0.02586 
total cholesterol 
enzymatic method 




mmol/l converted to 
enzymatic values 
from u2kolest by 
formulae u2kolenz=u2kolest u2kolenz=u2kolest 
u2hdlkol mg/dl, enzymatic* mg/dl, enzymatic* mg/dl, enzymatic* 
u2hdlkl 
converted to mmol/l 
by factor 0.02586 
converted to mmol/l 
by factor 0.02586 













from u1trigly by 
formulae u2trienz=u2trigly u2trienz=u2trigly 
Screening 3    
u3kolest/u3kolenz 
All values enzymatic mmol/l . Sometimes renamed u3kolest to 
u3kolenz to indicate that these are enzymatic values. 
u3hdlkl No measurements 
All values enzymatic 
mmol/l* 
All values enzymatic 
mmol/l* 
u3trigly/u3trienz 
All values enzymatic mmol/l . Sometimes renamed u3trigly to u3trienz 
to indicate that these are enzymatic values. 
*Eur Heart J. 1992 Sep;13(9):1155-63.   
High-density lipoprotein cholesterol and coronary, cardiovascular and all cause 
mortality among middle-aged Norwegian men and women.  
Stensvold I, Urdal P, Thürmer H, Tverdal A, Lund-Larsen PG, Foss OP. 
 
The cardiovascular surveys in Finnmark, Sogn og Fjordane and Oppland 1974-78,  
1977-83 and 1985-88. Sources: Final reports from each survey in each county 
 




% attendance,  
fully invited 
ages  
Finnmark 1974-75 All residents in age 35-49 by Dec 1974 
(born 25-39). Age 20-34: 10% random 
samples 
17401 14340 82.4  
Men: 78.8, 
women: 86.2 
 1977-78 All residents born 1925-42, samples in 
younger ages from 20 years. 
20647 17145 83.0 
Men: 79.2 
women: 87.3 
 1987-88 All residents in age 40-62 by Dec 1987 
(born 1925-47) + those aged 30-39 and 
invited in 1977-78 + 10 % of non-invited 
in age 20-39. All residents 18 years or 
older in Bugøynes.  





1975-76 All residents in age 35-49 by Dec 1975 
(born 1926-40) + 10 % random sample in 
age 20-39. 
16603 14966 90.1  
Men: 87.4, 
women:93.1 
 1980-81 All residents born 1926-40 + samples in 
younger ages from 17 years. 
19506 17473 89.6  
Men: 86.8, 
women:92.6 
 1985-86 All residents in age 40-54 by Dec 31 1985 
(born 1931-45) + those younger than 40 
years and invited in 1980-81  + 5-% 
sample of those in age 20-39 not invited in 
1980-81 +10 % sample of invited in 1980-
81 in age 55-59. A few older subjects in a 
hypertension register. 
21423 18669 87.1 
Men: 83.9, 
women: 90.7 
Oppland 1976-78 All in age 35-49 by Dec 1976 (born 1927-
41) +10- % random sample in age 20-39. 
31620 28399 89.8  
Men: 87.8, 
women: 91.8 
 1981-83 All residents born 1927-41 + samples in 
younger ages from 20 years. 
31581 28437 90.0  
Men: 88.1, 
women: 91.9 
 1986-88 All residents aged 40-54 on Dec 1986 
(born 1932-46) + all residents below 
40 years and a 10 % sample in age 55-
59 if invited in 1981-83 + 5-% of not 
invited in 1981-83 in age 20-39. A few 
older subjects in a hypertension 
register.  
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Cohort Norway (CONOR): Materials and methods 
Anne Johanne Søgaard, Norwegian Institute of Public Health, April 2006 
CONOR (COhort NORway) is a large collaborative project between 
epidemiological centres at the University of Tromsø, the Norwegian University of 
Science and Technology in Trondheim, the University of Bergen, the University 
of Oslo, and the Norwegian Institute of Public Health. 
 
Data from 10 regional studies 
In CONOR, regional data from 10 different epidemiological studies have been 
merged into a national database, which is more representative of the Norwegian 
population than each of the individual sites.  
 
The database consists of information obtained from questionnaires, a simple physical 
examination, analyses of blood samples, and frozen stored blood and/or DNA. The 
main purpose of CONOR is to study the aetiology of rare diseases by testing 
environmental, inheritable, cultural and social factors in order to describe the 
dispersion of diseases and risk factors by time, place and socio-demographic factors.  
 
CONOR is particularly suitable for studying gene-environment interactions and for 
linkages to various national registers (eg. cancer-, cause of death-, hospital- and 
medical birth registers). 
 
Invitation and procedures 
Altogether 309,832 individuals were invited in the 10 studies based on addresses from 
the Population registry of Norway (Hammer, 2002). Some of the individual studies 
invited all subjects above a specific age (for example all above 19 years in HUNT II), 
whereas others invited all subjects in selected age groups (for example all 30-, 40-, 
45-, 60 and 75 years in OPPHED and TROFINN). The web site for each study 
contains more detailed information (see Table 1).  
 
In all CONOR surveys, the data collection followed a standard procedure. Letters of 
invitation were mailed about 2 weeks before the time of appointment and included a 
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questionnaire and a booklet with the aims of the study and information about the 
examinations and procedures. At the screening, the main questionnaire was collected 
from the attendees, they went through a physical examination and a non-fasting blood 
sample was drawn for analyses in fresh serum. Another sample was stored at minus 
80 degrees. In most studies, the participants were given one or two supplementary 
questionnaires, which they were instructed to fill in at home and to return by mail in 
pre-addressed envelopes.  
 
About four weeks after attending the examination, a letter with some results from the 
examination and blood tests was sent to all participants. Those with the highest scores 
of cardiovascular risk were offered a new clinical examination at the regional 




All surveys have been carried out in collaboration with the National Health Screening 
Service, Oslo (now Norwegian Institute of Public Health). Experienced and trained 
personnel conducted all procedures. Non-fasting serum total and HDL cholesterol, 
glucose and triglycerides were measured directly by an enzymatic method 
(Boehringer 148393, Boehringer-Mannheim, Federal Republic of Germany – from 
2000 Hitachi 917 auto analyzer, Roche Diagnostic, Switzerland).  
 
The Department of Clinical Chemistry, Ullevål University Hospital, Oslo, performed 
all laboratory assessments except for HUNT II where the analyses were performed at 
the Department of Clinical Chemistry, Innherad Hospital, Levanger. Comparisons of 
blood-samples were performed between the laboratories, and small differences were 
found (Tverdal A et al 1997). Calibration procedures were carried out between these 
laboratories in connection with the surveys (Dr. Lund-Larsen PG, National Health 
Screening Service, personal communication). An acceptable stability of the laboratory 
analyses over time in the population surveys has been reported (Foss & Urdal, 2003). 
 
Heart rate, systolic and diastolic blood pressures were measured by an automatic 
device (DINAMAP, Criticon, Tampa, USA), which measured the blood pressure in 
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mm Hg automatically by an oscillometric method. After 2 minutes of preceding rest, 
three recordings were made at one-minute intervals. Mean values of the second and 
third systolic blood pressure measurements were used in calculating the 
cardiovascular risk score (CVD risk score) (Tverdal et al., 1989). The stability of the 
blood-pressure measures have been evaluated and deemed acceptable (Lund-Larsen, 
1997). 
 
Body weight (in kilograms, one decimal) and height (in cm, one decimal) was 
measured according to a standard protocol with the participants wearing light clothing 
without shoes (manually recorded until 2000 and after that with an electronic Height 
and Weight Scale). Body mass index (BMI) was calculated as kg/m2. Waist 
circumference was measured at the umbilicus to the nearest cm and with the subject 
standing and breathing normally. In obese individuals, waist circumference was 
defined as the midpoint between the iliac crest and lower margin of ribs. Hip 
circumference was measured as the maximum circumference around the buttocks. 
Both waist and hip were measured with a measuring tape of steel – which was 
emphasized to be horizontal. Waist and hip circumference were used to calculate the 
waist-hip ratio using the formula waist (cm)/ hip circumference (cm). 
 
Most of the studies consist of a central core and several supplementary projects – for 
example extra samples of blood, ECG, ultrasonographic examination of carotid artery 
and abdominal aorta, and bone mineral densitometry (BMD). The web site for each 
study contains more detailed information (see Table 1). Only a limited and mutual 
core of each study constitutes CONOR. Most of the studies have published reference 
papers with more detailed information about their own study (Table 2). 
 
The CONOR-questions 
All surveys used 50 common CONOR-questions agreed upon before the first CONOR 
survey in Tromsø in 1994. The exact wording of the questions is available at the 
CONOR web site (http://www.fhi.no/dav/CA11310499.doc). Some of these 
questions were placed on the second questionnaire handed out at the screening station 
– and thus have lower response rate.  
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The CONOR-questions cover the following main topics: Self-reported health and 
diseases such as diabetes, asthma, coronary heart disease, stroke and mental distress, 
musculo-skeletal pains, family history of disease, risk factors and lifestyle, 
environment while growing up, social network and social support, education, work 
and housing, some types of occupation, use of medications and reproductive history 
(women).  
 
Several of these questions have been evaluated or validated previously and were 
deemed acceptable (Tretli et al., 1982; Jacobsen & Thelle, 1987; Løchen & 
Rasmussen, 1992; Thune et al., 1997, Joakimsen et al., 1998; Saltin & Grimsby, 1968; 
Derogatis et al., 1974; Ainsworth et al., 1996; Brugha et al., 1985; Strand et al., 2003; 
Søgaard et al 2003). The Population registry of Norway, which was used for 
invitation, contains information about gender, birth date, marital status, address and 
country of birth.  
 
Participation in the CONOR studies 
Altogether 181,891 subjects accepted to participate and provided a declaration of 
consent – 7,460 of these participated in more than one survey. The age distributing of 
these 174 430 participants is shown in table 3. The participation rate varied among the 
surveys. The participation was slightly reduced throughout the study-period 1994-
2003 - and was higher in rural as compared to urban areas.  
   
Ethics and approvals 
All participants of the studies included in CONOR, have given their written consent. 
The participant’s names and personal ID numbers are omitted when data are used for 
research purposes. The Norwegian Data Inspectorate has approved - and the Regional 
Committees for Medical Research Ethics has evaluated each individual study. The 
studies have been conducted in full accordance with the World Medical Association 
Declaration of Helsinki.  
 
October 2007 5 
References 
Ainsworth BE, Montoye HJ, Leon AS. Methods of assessing physical activity during 
leisure and work. In: Bouchard C, Shephard RJ, Stephens T (red.) Physical activity, 
fitness and health. Champaign, IL: Human Kinetics, 1994: 146-59. 
Brugha, T, Bebbington, P, Tennant, C, Hurry, J. The list of threatening experiences: a 
subset of 12 life event categories with considerable long-term contextual threat. 
Psychol Med, 1985;15:189-194. 
Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L. The Hopkins Symptom 
Checklist (HSCL): a self-report symptom inventory. Behav Sci 1974;1:1-15. 
Engeland A, Søgaard AJ. CONOR (COhort NORway) – en oversikt over en unik 
forskningsdatabank. Norsk Epidemiologi 2003; 13 (1): 73-77 73. 
Jacobsen BK, Thelle DS. The Tromso Heart Study: food habits, 
serum total cholesterol, HDL cholesterol, and triglycerides. Am J 
Epidemiol 1987; 125:622-630. 
Foss O, Urdal P. Cholesterol for more than 25 years: Could the 
results be compared throughout all this time [Kolesterol gjennom 
mer enn 25 år: Kan svarene sammenliknes over så lang tid?]  Nor J 
Epidemiol 2003;13:85-8. 
Hammer H. The central population registry in medical research [Article in 
Norwegian]. Det sentrale folkeregisteret i medisinsk forskning. Tidskr Nor 
Laegeforen 2002;122:2550. 
Joakimsen RM, Fønnebø V, Magnus JH, Størmer J, Tollan A, Søgaard AJ. The 
Tromsø study: Physical activity and the incidence of fractures in a middle-aged 
population. J Bone Min Res 1998; 13: 1149-57. 
Lund-Larsen PG. Blood pressure measured with sphygmomanometer and with 
Dinamap under field conditions – a comparison [Article in Norwegian]. Blodtrykk 
målt med kvikksølvmanometer og Dinamap under feltforhold – en sammenligning. 
Nor J Epidemiol 1997;7:235-41.  
October 2007 6 
Løchen MJ, Rasmussen K. The Tromsø study: physical fitness, self reported physical 
activity, and their relationship to other coronary risk factors. J Epidemiol Com Health 
1992; 46: 103-7. 
Magnus, P, Arnesen E, Holmen J, Stoltenberg C, Søgaard AJ, Tell G. CONOR – 
COhort NORway: historie, formål og potensiale. Norsk Epidemiologi 2003; 13 (1): 
79-82 79. 
Saltin B, Grimsby G. Physiological analysis of middle-aged and old former athletes. 
Circulation 1968; 38: 1104-15. 
Strand BH, Dalgard OS, Tambs K, Rognerud M. Measuring the mental Health Status 
of the Norwegian Population: a comparison of the instruments SCL-25 SCL-10, SCL-
5 and MHI-5 (SF-36). Nord J Pschychiatry 2003;57:113-8. 
Søgaard AJ, Bjelland I,Tell, GS, Røysamb E. A comparison of the CONOR Mental 
Health. Index to the HSCL-10 and HADS. Measuring mental health status in The 
Oslo Health Study and the Nord-Trøndelag Health Study. Nor J Epidemiol 2003; 13 
(2): 279-284 279. 
Thune I, Brenn T, Lund E, Gaard M. Physical activity and the risk of breast cancer. N 
Engl J Med 1997; 336: 1269-75. 
Tretli S, Lund-Larsen PG, Foss OP. Reliability of questionnaire information on 
cardiovascular disease and diabetes: cardiovascular disease study in Finnmark county. 
J Epidemiol Community Health 1982; 36:269-273. 
Tverdal A, Foss OP, Leren P, Holme I, Lund-Larsen PG, Bjartveit K. Serum 
triglycerides as an independent risk factor for death from coronary heart disease in 
middle-aged Norwegian men. Am J Epidemiol 1989;129:458-65. 
Tverdal A, Åsberg A, Bønaa KH, Stensvold I, Grudt G, Ingebretsen OC, Urdal P. 
Sammenligning av to blodprøver fra samme person analysert ved to laboratorier. 
Norsk Epidemiologi 1997; 7 (2): 283-286. 
 
October 2007 7 
TABLE 1. Number of invited and participating subjects in Cohort Norway (CONOR) 1994-2003. 
    Number of participants * 
 






groups in years‡ 
Men Women Total Web address 
Tromsø IV (The fourth Tromsø Study) 1994-1995 37,558 25 + 12,797 14,128 26,925 http://uit.no/tromsoundersokels
en/tromso4/2 
HUNT II (The second North-Trøndelag Health Study) 1995-1997 94,196 20 + 30,442 34,576 65,018 http://www.hunt.ntnu.no/ 
HUSK (The Hordaland Health Study) 1997-1999 38,587 40-44, 46-47, 70-
72 
11,678 13,852 25,530 http://www.uib.no/isf/husk/ 
Oslo II (The second Oslo Study)  2000 14,209§ 48-77 6,919  6,919 http://www.fhi.no/artikler/?id=54
685 
HUBRO (The Oslo Health Study)  2000-2001 58,660# 30, 31, 40, 45, 
46, 59/ 60,  
75/ 76 
9,751 12,264 22,015 http://www.fhi.no/artikler/?id=5
4464 
OPPHED (The Oppland and Hedmark Health Study) 2000-2001 22,327 30, 40, 45, 60, 75 5,650 6,752 12,402 http://www.fhi.no/artikler/?id=2
8233 
Tromsø V (The fifth Tromsø Study) 2001 10,353 30 + 3,491 4,586 8,077** http://uit.no/tromsoundersokels
en/tromso5/2  
I-HUBRO (The Oslo Immigrant Health  Study) 2002 12,088†† 20-60 1,915 1,768 3,683 http://www.fhi.no/artikler/?id=2
8217 
TROFINN (The Troms and Finnmark Health Study) ‡‡ 2002 16,229 30-77 4,318 5,009 9,327 http://www.fhi.no/artikler/?id=2
8261 
MoRo II (The second part of the Romsås in Motion Study) 2003 5,535 34-70    899 1,096 1,995 http://www.fhi.no/artikler/?id=2
8254 
 

















*  Number of participants equals those who attended the survey and/or answered at least one questionnaire and signed a written consent. 7,460 persons participated in a second 
CONOR survey and 1 person participated in a third. Thus, the total numbers of participants with consent were 174,430. 
†  The numbers include all individuals invited. The individual surveys could have published papers with slightly different total numbers.  
‡  HUSK: All 40-44 years and those participating in a study in 1992-93 born 1950-51 and 1925-27; Oslo II: All those invited to the Oslo Study 1972-73, except those invited to 
HUBRO and MoRo I (Invited in 1972/73: all men born 1923-32 and 7% random sample of those born 1933-52); Tromsø V: All 30, 40, 45, 60, 75 years and all those participating in 
phase II in Tromsø IV - which included: all born 1920-1939, 5-10% sample of other age groups attending phase I, all women born 1940-44; I-HUBRO: 30% random sample of people 
born in Pakistan, all born in Turkey, Sri Lanka, Iran, Vietnam - except those invited to HUBRO;  MoRo II: All those participating in a study in 2 local districts in Oslo in 2000 (MoRo 
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I) born 1933-1969 – except those participating in HUBRO; TROFINN: All 30, 40, 45, 60, 75 years and all those participating in three Finnmark studies in the period 1974-1988 – 
which included: All born 1925-1947, all born 1948-1968 invited to Finnmark I, II or III.  
§  2,515 more men who belonged to the Oslo II cohort, also belonged to the HUBRO cohort, and were only invited to HUBRO. Of these 1,320 men participated. They are only 
counted as invited to HUBRO. 50 more men belonged to the MoRo-cohort, and are only counted as invited there. 
#  Include 17,308 invitees (31 and 46 years – additional cohorts) who were not reminded. The attendance-rate of these was low.  
** 7,166 of these participated also in Tromsø IV. 
†† Include 4,116 persons (20-30 years – additional cohort) who were not reminded. The attendance-rate of these was very low. 
‡‡ Include 18 of 25 municipalities in Troms and 10 of 19 municipalities in Finnmark. The other municipalities participated in Tromsø V and in SAMINOR, i.e. a health survey in 






Table 2. Reference papers to the 10 participating CONOR studies. 
 
Tromsø IV: Wilsgard T. Longitudinal analyses of cardiovascular risk factors. The Tromsø study 1974-1995. ISM skriftserie nr. 65. Tromsø, 
Norway: Institute of Community Medicine, University of Tromsø, 2002. 
HUNT II: Holmen J, Midthjell K, Krüger Ø, Langhammer A, Lingaas Holmen T, Bratberg GH, Vatten L, Lund-Larsen PG. The Nord-Trøndelag 
Health Study 1995-97 (HUNT 2): Objectives, contents, methods and participation. Nor J Epidemiol 2003; 13: 19-32. 
HUSK: Bjelland I, Tell GS, Vollset SE, Refsum H, Ueland PM. Folate, vitamin B12, homocysteine, and the MTHFR 677C->T polymorphism in 
anxiety and depression: the Hordaland Homocysteine Study. Arch Gen Psychiatry 2003 Jun;60(6):618-26 - and 
Sanne B, Mykletun A, Dahl AA, Moen BE, Tell GS; Hordaland Health Study. Occupational differences in levels of anxiety and depression: the 
Hordaland Health Study. J Occup Environ Med 2003;45:628-38. 
Oslo II: Lund  Håheim L, Holme I, Hjermann I, Søgaard AJ, Lund-Larsen PG, Leren P. Resultater fra Oslo-undersøkelser blant de samme menn i 
1972/3 og i år 2000. Endring i risikofaktorer for hjerte- og karsykdom. Tidskr Nor Laegefor (Cond accepted)  
HUBRO: Søgaard AJ, Selmer R, Bjertness E, Thelle D. The Oslo Health Study. The impact of self-selection in a large, population-based survey. Int 
J Equity Health 2004:3: 1-24. Online: http://www.equityhealthj.com/content/3/1/3 
OPPHED: Only web-site - http://www.fhi.no/artikler/?id=28233 
Tromsø V: Johnsen SH, Fosse E, Joakimsen O, Mathiesen EB, Stensland-Bugge E, Njølstad I, Arnesen E. Monocyte count is a predictor of novel 
plaque formation: a 7-year follow-up study of 2610 persons without carotid plaque at baseline the Tromso Study. Stroke. 2005;36(4):715-9.  
I-HUBRO: Holvik K, Meyer HE, Haug E, Brunvand L.Prevalence and predictors of vitamin D deficiency in five immigrant groups living in Oslo, 
Norway: the Oslo Immigrant Health Study. Eur J Clin Nutr. 2005;59:57-63. 
TROFINN: Only web-site - http://www.fhi.no/artikler/?id=28260 
07.07.06 
MoRo II: Jenum AK,. Anderssen SA, Birkeland KI, Holme I, Graff-Iversen S, Lorentzen C, Ommundsen Y, Raastad T, Ødegaard AK, Bahr R. Promoting 
physical activity in a low-income multi-ethnic district: behavioural, psychological and biological effects of a pseudo-experimental community 
intervention study to reduce risk factors for diabetes and cardiovascular disease (submitted) 
CONOR: Engeland A, Søgaard AJ. CONOR (Cohort NORway) – en oversikt over en unik forskningsdatabank. Nor J Epidemiol 2003;13:73-7 - and 





Table 3 Number of participants in Cohort Norway (1994-2003)  
according to gender and age-groups (at the time they attended 
the screening station). If participating in more than one study,  
only the last one is counted. 
 
 Men  Women  Total 
Age N  N  N 
<20 116  148  264 
20-29 5 884  7 236  13 120 
30-39 13 322  15 547  28 869 
40-49 27 969  32 148  60 117 
50-59 10 517  10 176  20 693 
60-69 12 229  10 373  22 602 
70-79 13 119  11 883  25 002 
80+ 1 460  2 303  3 763 
Total 84 616  89 814  174 430 
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How did the study come about?
A number of large population-based cardiovascular surveys
have been conducted in Norway since the beginning of the
1970s. The surveys were carried out by the National Health
Screening Service in cooperation with the universities and local
health authorities. All surveys comprised a common set of
questions, standardized anthropometric and blood pressure
measurements and non-fasting blood samples that were
analysed for serum lipids at the Ullevål Hospital Laboratory.
These surveys provided considerable experience in conducting
large-scale population-based surveys, thus an important back-
ground for the Cohort of Norway (CONOR). In the late 1980s
the Research Council of Norway established a programme in
epidemiology. This also gave stimulus to the idea of establish-
ing a cohort including both core survey data and stored blood
samples. In the early 1990s, all universities, the National Health
Screening Service, The National Institute of Public Health and
the Cancer Registry discussed the possibility of a national
representative cohort.1 The issue of storing blood samples for
future analyses raised some concern and it was discussed in the
parliament. In 1994, the Ministry of Health appointed the
Steering Committee for the CONOR collaboration. In 1994–95,
the fourth round of the Tromsø Study was conducted, and
became the first survey to provide data and blood samples for
CONOR. During the years 1994–2003, a number of health
surveys that were carried out in other counties and cities also
provided similar data for the network. So far, 10 different
surveys have provided data and blood samples for CONOR
(Figure 1). The administrative responsibility for CONOR was
given to the Norwegian Institute of Public Health (NIPH) in
2002. The CONOR collaboration is currently a research
collaboration between the NIPH and the Universities of
Bergen, Oslo, Tromsø and Trondheim.
The purpose of CONOR
The CONOR cohort has not been established on the basis of any
single hypothesis but is rather a multipurpose study. The
ambition was to set up a sufficiently large enough cohort to
study aetiological factors for a wide range of diseases.
Additionally, this cohort should make it possible to describe
Norwegian men and women in terms of distribution of
exposures and health status according to time, place and
socio-economic factors.
In 2002, CONOR and the Norwegian Mother and Child study
(MoBa),2 received a 5-year grant from the Norwegian Research
Council to build a technology platform under the Functional
Genomics programme (FUGE), called the Biobanks for Health
in Norway (Biohealth) platform.3 The overall aim was to
investigate separate and combined effects of genes and
environment on the risk of disease.
Who is in the sample?
Altogether 309 742 individuals were invited to the 10 surveys
based on the 11-digit personal identifier and addresses from the
Population Registry of Norway.4 The goal is to include 200 000
participants. We defined those who attended the survey and/or
answered at least one questionnaire and signed a written
informed consent as participants. The numbers in Table 1
include individuals who participated and had given their
written consent for research and linkage to health registries.
A total of 7309 persons participated in two CONOR surveys, and
one person participated in three. Thus, the total number of
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individuals in the CONOR cohort is 173 236. The distribution of
age at the first examination and the number of deaths during
follow-up through 2003 is given in Table 2. The individual
surveys may have published papers with slightly different total
numbers. Sampling procedures differed somewhat between the
individual studies. The web site for each study contains more
detailed information (Table 1).
What has been measured?
In all the CONOR surveys, the data collection followed
a standard procedure. Letters of invitation were mailed about
2 weeks before the time of appointment and included a
questionnaire and a brochure with the aims of the study and
information about the examinations and procedures. At the
screening, this initial questionnaire was collected from the
attendees, participants underwent a physical examination and
a non-fasting blood sample was drawn. In most studies, the
participants were given one or two supplementary question-
naires, which they were instructed to fill in at home and return
by mail in pre-addressed stamped envelopes.
About 4 weeks after attending the examination, a letter with
selected results from the examination and blood tests was sent
to all participants. Those with the highest scores of cardiovas-
cular risk (a modified Framingham risk score based on
multiplying the relative risks attributable to the subject’s
gender, serum cholesterol, systolic blood pressure the number
of cigarettes currently smoked per day and family history of
Table 1 Number of invited and participating subjects in cohort of Norway (CONOR) 1994–2003









Men Women Total Web address
Tromsø IV (The fourth Tromsø
Study)
1994–1995 37 558 25þ 12 797 14 128 26 925 http://uit.no/tromsoundersokelsen/tromso4/2
HUNT II (The second
North-Trøndelag Study)
1995–1997 94 196 20þ 30 441 34 576 65 017 http://www.hunt.ntnu.no/
HUSK (The Hordaland Health
Study)
1997–1999 38 587 40–44, 46–47,
70–72
11 678 13 851 25 529 http://www.uib.no/isf/husk/
Oslo II (The second Oslo Study) 2000 14 209 48–77 6919 6919 http://www.fhi.no/artikler/?id¼54685
HUBRO (The Oslo Health Study) 2000–2001 58 660 30, 31, 40, 45,
46, 59/60,
75/76
9509 11 852 21 361 http://www.fhi.no/artikler/?id¼54464
OPPHED (The Oppland and
Hedmark Health Study)
2000–2001 22 327 30, 40, 45,
60, 75
5602 6661 12 263 http://www.fhi.no/artikler/?id¼28233
Tromsø V (The fifth Tromsø
Study)
2001 10 353 30þ 3440 4457 7897 http://uit.no/tromsoundersokelsen/tromso5/2
I-HUBRO (The Oslo Immigrant
Health Study)
2002 12 088 20–60 1877 1737 3614 http://www.fhi.no/artikler/?id¼28217
TROFINN (The Troms and
Finnmark Health Study)
2002 16 229 30–77 4196 4836 9032 http://www.fhi.no/artikler/?id¼28261
MoRo II (The second part of
the Romsås in Motion Study)
2003 5535 34–70 896 1093 1989 http://www.fhi.no/artikler/?id¼28254
CONOR (Cohort Norway)a 1994–2003 309 742 20–103
Sum of participants 87 355 93 191 180 546 http://www.fhi.no/artikler/?id¼28138
Sum of individuals 84 153 89 083 173 236
aNumber of participants equals those who attended the survey and agreed that information from the CONOR survey and blood samples can be
linked to other registers and used in research. A total of 7310 individuals participated in more than one survey. Thus, the total number of individuals
equals 173 236.
Figure 1 Map of Norwegian counties with location of each sub-study
included in cohort of Norway (CONOR)
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coronary heart disease) were advised to visit their own general
practitioner, and in some cases offered a follow-up examination
at the local hospital.5
Measures
Only a restricted core set of measurements and questionnaire
responses constitute the CONOR data. Most individual studies
that contribute to CONOR have more detailed measurements and
questionnaire data. In the following section we describe the key
core measurements that all studies contribute to CONOR; at the
end we briefly describe some of the additional measurements
that are in some of the contributing individual studies. All surveys
were carried out in collaboration with the National Health Screen-
ing Service, Oslo (now the NIPH). Experienced and trained
personnel conducted all procedures. Non-fasting serum total-
and HDL-cholesterol, glucose and triglycerides were measured
directly by an enzymatic method (Boehringer 148393, Boehringer-
Mannheim, Federal Republic of Germany—from 2000 Hitachi 917
auto analyzer, Roche Diagnostic, Switzerland).
The Department of Clinical Chemistry, Ullevål University
Hospital, Oslo, performed all laboratory assessments except for
HUNT II (The second North-Trøndelag Study) where the analyses
were performed at the Department of Clinical Chemistry, Levanger
Hospital, Levanger. In Tromsø IV and V, cholesterol and triglycer-
ides were measured at the Department of Clinical Chemistry,
University Hospital North-Norway, Tromsø. Calibration procedures
were carried out between these laboratories in connection with the
surveys (Dr P.G. Lund-Larsen, National Health Screening Service,
personal communication). An acceptable stability of the laboratory
analyses over time in the population surveys has been reported.6
Heart rate, systolic and diastolic blood pressures were mea-
sured by an automatic device (DINAMAP, Criticon, Tampa,
FL,USA). After 2 min of seated resting, three recordings were
made at 1-min intervals. Mean values of the second and third
systolic blood pressure measurements were used in calculating
the cardiovascular risk score (CVD risk score) (Tverdal, 1989
5/id). The stability of the blood pressure measures has been
evaluated and deemed acceptable.7
Body weight (in kilograms, one decimal) and height (in
centimetres, one decimal) was measured according to a standard
protocol with the participants wearing light clothing without
shoes (manually recorded until 2000 and after that with an
electronic Height and Weight Scale). Body mass index (BMI) was
calculated as kilograms per square metre. Waist circumference
was measured at the umbilicus to the nearest centimetre and with
the subject standing and breathing normally. In obese individuals,
waist circumference was defined as the midpoint between the iliac
crest and lower margin of ribs. Hip circumference was measured
as the maximum circumference around the buttocks. Both waist
and hip were measured with a measuring tape of steel—which
was emphasized to be placed horizontally. The waist–hip
circumferences were used to calculate the waist–hip ratio.
Most individual studies that contribute to CONOR have
several additional measurements—for example, extra samples
of blood, ECG and ultrasonographic examination of carotid
artery and abdominal aorta. Four of the study sites measured
bone mineral density (DEXA and/or SXA) and have established
a research group called Norwegian Epidemiologic Osteoporosis
Studies (NOREPOS).8 Altogether, around 28 000 individuals
have had their bone mineral density measured and currently a
number of collaborative studies are carried out.
The CONOR questions
All surveys used about 50 core CONOR questions agreed upon
before the first CONOR survey in Tromsø in 1994. The exact
wording of the questions is available at the CONOR website
(http://www.fhi.no/dav/CA11310499.doc). Some questions have
been slightly modified over the years.
The CONOR questions cover the following main topics: self-
reported health and diseases such as diabetes, asthma, coronary
heart disease, stroke and mental distress, musculo-skeletal
pains, family history of disease, risk factors and lifestyle, social
network and social support, education, work and housing, some
types of occupation, use of medications and reproductive
history (women).
Several of the questions have been evaluated or validated and
deemed acceptable.9–18 The Population Registry of Norway that
was used to identify eligible subjects, contains information about
gender, date of birth, marital status, address and country of birth.
Blood samples
Blood samples were drawn from the CONOR participants. EDTA
blood for CONOR and the other sub-surveys have normally
been collected in 7 or 5 ml vacutainers. These vacutainers were
made by different manufacturers but were normally made of
polypropylene. DNA has been extracted from more than 90 000
specimens to medio 2007, and Biohealth intends to extract
DNA from all samples by Spring 2008. The extracted DNA and
an additional sample of 1.25 ml EDTA-blood will be stored at a
national biobank storage site at HUNT/NTNU biobank in
Levanger (Mid-Norway).
What has been found?
Although a number of analyses from each participating study
have been conducted, the CONOR file has only recently been
compiled and made available for research. The first CONOR
project was anchored in NOREPOS describing urban–rural
differences in forearm fractures.19 Other methodological and
validation studies have been completed as described above.
What are the main strengths and
weaknesses?
The CONOR database has several strengths: it is population
based including populations from various parts of Norway, both
rural and urban. The 11-digit personal identification number
makes it possible to link cohort participants to national health
registries. At present, several large linkages to other registers
have been or are in the process of being conducted. These
include linkages with census-based data for the whole
population and the Medical Birth Registry of Norway,
Disability Registry, Cancer Registry of Norway. Tables 2 and 3
present number of deaths and new cases of cancer in CONOR
since date of examination by linkage to the death and cancer
registries. Other large linkages include data from the
Norwegian Drug Prescription Database and information from
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health surveys in several counties in the 1970s. There are also a
number of disease registers that may be linked to the CONOR
database. Earlier this year, the government passed a new
legislation to make the national hospital discharge register
personal identifiable, which would be possible to link to
CONOR in the near future.
A major strength of CONOR is its sample size that means it
would be able to make a unique contribution to establish main
genetic effects and gene–environmental interactions, since
precise and robust estimation of these effects requires very
large sample sizes.20,21 Our aim is to reach 200 000 individuals
with blood samples and extracted DNA and we anticipate
reaching this sample size by Spring 2008. For some hypotheses,
it would be most efficient to employ a nested case control study
design within CONOR, and we anticipate several such studies
in the future. This comparatively large sample size means cases
for a number of common and less common diseases may be
identified from various sources.
There are some important weaknesses: the overall participa-
tion rate is 58% and is lowest in the surveys in Oslo and other
urban areas and became lower throughout the study period.
However, the overall participation rate is influenced by low
participation rate in those aged 430 years. The study
population is somewhat heterogeneous as it includes sampling
from 10 geographical areas with various age groups included
over a 10-year period. The number of core variables is limited,
and in some cases the wording of questions is slightly changed
over the years.
Can I get hold of the data? Where
can I find out more?
Guidelines have been developed for projects using data from
CONOR (www.fhi.no). These shall ensure that projects will
have a high scientific quality, facilitate quick publication of
results from CONOR and make the data accessible for research.
Research groups may apply for access. A project leader must be
appointed. Researchers not residing in Norway are advised to
seek contact with Norwegian counterparts. The study objectives
should be within the broader aims of CONOR. Further details
of these guidelines are provided at the CONOR website.
Applications and enquiries can be sent electronically to the
Norwegian Public Health Institute (email: conor@fhi.no).
Applications will be evaluated by the CONOR Steering
Committee.
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Lawlor (2004) UK 3 139/3047 1.06 (0.72-1.56) for 
smoking BFC 
Smoking before first childbirth only. 
Cohort study and meta-analysis. Cohort 
study has 3 years follow up. Non 
significant findings.
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Former 1.4 (0.4-3.5)
Not incl due to low number of cases (14 
current, 4 former). Prevalence current 
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Young age 1.48 (1.03-
2.13) Higest PY 1.46 
(1.11-1.93)
10
Analysis for pre and postmenopausal
1.27 (1.07-1.37)
No modification by alc use. Risk estimate 
by ever/never.
1.21 (1.01-1.25)14 2017/41836
Duration before first 
preg 1.21 (1.01-1.25)
Positive associtaion with post-menopausal 
BC, but no dose-reponse.
Al-Delaimy 
(2004)
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(-) (-) 1.10 (1.07-1.14)
Only focus: first pregnancy. Meta-analysis. 
Similar risks smoking only before and only 











Ever 1.06 (1.01-1.10) 
Former 1.05 (1.00-1.10) 
Current 1.06 (1.00-1.12) 
- passive in reference 
group.
1.73 (1.29-2.32) for 
every PY before 1 first 
childbirth.
Largest study to date (cases). Found strong 
association for increase 20PY before first 
childbirth. Mostly no ass for high PY ! 
Increased risk among non-drinkers only. 
Passive excluded from reference group in 
some analysis.
Included and 
discussed. Stronger ass 
for current smokers 
with low edu HR=1.21 







14 97786 Current 1.14 (1.07-1.42) 
Former 1.13 (1.06-1.42)
 8.2% current smokers at enrollment. 
Meta-analysis of 14 studies- concludes 
positivelly.No alc association but no info of 
amount(dose).
Incl in main model
In model but not 
commented elsewhere
Not mentioned




No modification by alc use. Edu in main model
Not in main model
Focus: smoking before first childbirth. 
Higher risk among postmenopausal. No 
risk for smoking after  FCB.
45% increased risk when smoking 11 or more 
years before first birth: 1.45 (1.21-1.74)











Highest PY 1.27 (1.16-
1.38). Smoking from 
menarche to first birth: 
1.18 (1.10-1.27) for 












Smoking >50 years: HR 
1.35 (1.03-1.77)
Large no of cases. Analysis for pre- and 
postmenopausal (no difference). Not used 
as reference for passive (no association). 
Biannual collection of smoking data. 
1.25 (1.11-1.40)
1.21 (1.11-1.33)
Active (and passive) smoking in 
postmenopausal women only. Also 
reference for passive smoking.
1.39 (0.82-2.35) ≥ 10 
pack years before
906/ 5604215
Cui (2006) 16 4445/89835
   
years 1.50 (1.19-1.89)








Current 1.05 (0.83-1.31) 
Former 1.10 (0.90-1.35)       
Ever 1.08 (0.89-1.31) 
Premonp 2.01 (1.10-3-
65) Postmenop 0.88 
(0.55.1-39)
 Increased risk for premonopausal cancer 
when smoking before frist childbirth. No 
increase for postmenopausal. NS for 
overall (current, former, ever).
Incl in main model. 
Glantz and 
Johnson (2014)










Current 1.19 (1.10-1.28)  
Former 1.07 (1.01-1.13)
1.22 (1.11-1.35) for 
smoking 11-20 cig/day
Poor dose-responce. Stronger ass for 
family history and late menarche. Adj for 
age at enrollment.






6 604412 Current 1.26 (1.05-1.50) 
Former 0.85 (0.70-1-03)
>40 cig per day 1.74 
(1.15-2.62)






Current 1.44 (1.01-2.06) 






Nurses Health 8 5056
Current 1.00 (0.83-1.19) 
Prediagnosis smoking 
status: Current 1.03 
0.87-1.22
Main analysis done on prediagnostic 
smoking status. Increased risk for total 
mortality, no risk for BC mortality.
No effect even for all cause survival and 
smoking. Confusing use of terms.
Sagiv (2007) Long Island 
Breast Cancer 
6 1273 Current 1.04 (0.63-1.71) 
Former 0.89 (0.57-1.40)
Braithwaite 







Current (survival): 2.01 
(1.27-3.18)
Review on survial. Confusing assessment 
of mortality and survival. But strong 
association found for survival (NB low no 
of cases:16) in both prosp analysis and 
review with current, NOT former. Nice 
overview of surveys. Smoking assessment 
2 years post diagnosis.
Pirie (2012)
Million Women 
Study 12 1.3 mill
Mortality for breast 1.13 
(1.04-1.22)
Lancet. Smoking and disease spesific 
mortality, and overall mortality. Analysis 
on non-drinking women changed results 
to non-significant 1.06 (0.95-1.18).
Warren (2013) Roswell Park 12
Current survival: 1.71 
(1.28-2.29)








Current survival: 1.12 
(0.67-2.24), former 1.08 
(0.82-1.40).
Lifetime exposure 20+ 
PY (mortality): 1.54 
(1.07-2.32)
Discussing the benefit of assessing 
llifetime smoking exposure instead of 
current or former smoking at diagnosis. of 
mortality before survical. For survival: no 
significant results. NB Less than 5% current 
smokers, one third of those with >20 pack-
years history.
Pierce (2013)
3 US cohorts 
(WHEL, LACE, 
NHS)
11 1059/9975 Former >=35 pack 
years: 1.54 (1.24-1.91)
JNCI. Compare with Saquib (2013). 
Lifetime exposure assessed for former 
smokers at diagnosis. NB very high 
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Inclusions selected on survey from data manager: 
 
3 Counties I 62 220 
3 Counties II 9 188 
3 Counties III 22 538 
CONOR 137 182 
40 Years (total) 403 691 
































Analytical cohort: 602, 242( m=299,376, f=302,866) 
 
Cancer cases in cohort by smoking status 
 
 Never-smokers Former-smokers Current-smokers Total 
Breast cancer 3,028 1,581 2,881 7,490* 
Colon cancer 1,368 1,099 1,531 3,998 
Rectal cancer| 648 602 926 2,176 
 





Cancer Mortality in cohort by smoking  
 
 
 Never-smokers Former-smokers Current-smokers Total 
Breast cancer 459 216 431 1,106* 
Colon cancer 1,607 443 642 1,607 
Rectal cancer| 202 181 343 726 
 










The daily-smokers variable in CONOR was based on question “Do you smoke daily?” (In 
CONOR, this question includes cigarettes, pipe and cigar daily smokers, according to 
CONOR documentation (variable a8_0)). 
 
In Oslo health study I, the question “Do you smoke daily?” is used for current smokers. 





In the Norwegian counties study (I, II and III), this was based on the question “Do you smoke 
daily now?” A positive answer will give a categorization of daily smoker. (We do not 
consider other answers regarding smoking to classify the current smokers.)  
 
40 years I was based on the question “Do you smoke daily now?” Answering “Yes” will be 
current smokers.  
 
40 years II was based on the questions “Do you smoke cigarettes daily? Or “Do you smoke 
cigar daily?” “Do you smoke pipe daily?” answering “Yes” to any of these questions gives 
daily-smokers. 
 
The 40 years III and IV was based on “Do you smoke cigarettes daily?” or “Do you smoke 
cigar daily?” or “Do you smoke pipe daily?” If participants have answered “Yes” on any of 







After we got all current smokers, then we categorized remaining participants in the former-
smokers category as below: 
In CONOR if participants have valid answer (greater than 0) in questions “How long time 
since quit smoking (a_9)?” or numbers of cigarettes smoking daily (a_10) or “How old were 
you when you start smoking (a_11)? or “How many years of smoking in total(a_12_1).?” 
,then  categorized as former- smokers. 
 
Oslo study I: Those who answered “Yes” to the question “Have you smoked cigarettes daily 
previously” (tidlrok) in Oslo health study were classified as former smokers. In addition, we 
check if a valid value on (tidsidsl) “How long since quitting?!”, if there is a valid value then 
we categorized them as former smokers. 
 
In the Norwegian counties those answering “Yes” to the questions “Have you smoked 
cigarettes daily previously?” were categorized as former-smokers. If answering any value 
(except zero) to the question “How long since you quit smoking?”, and “How many years 
have you smoked daily?” and “how many cigarettes do you or did you smoke daily?”, and not 
a current smoker, then categorized as a former smoker. 
40 years I and II is done similar as the Norwegian Counties. Those answering “Yes” to the 
questions “Have you smoked cigarettes daily previously?” were categorized as former-




smoking?”, and “How many years have you smoked daily?” and “how many cigarettes do you 
or did you smoke daily?”, and not a current smoker, then categorized as a former smoker. 
(Please note the comment from Randi about classification this question in 40 years II.) 
40 years III and IV: any answer more than zero in the question “if you have smoked 
previously, how long since you quit?” then a former smoker. (As answering option is in years, 
we might misclassify those answering zero because they have quit less than 1 year ago.) Also, 
answering any value more than zero to the questions “how many cigarettes do you smoke or 
did you smoke daily”, “how old were you when you started to smoke daily?” or “how many 
years have you smoked daily?”, then classified as former smoker, if not already classified as a 
current smoker. 
 
After we have categorized current and former-smokers, from the remaining group of 
participants, we categorized never-smokers in the following ways: 
 
Never smokers 
CONOR: Answering “No” to the question “Do you smoke daily (a8_0)?”  then never 
smokers. 
In the Norwegian counties study, participants  answering “No” in the questions “Do you 
smoke cigarettes daily?” or Do you smoke cigars daily?” or Do you smoke pipes daily?” and 
if answering  “No” to  the question “Have you smoked cigarettes daily previously?” were 
categorized as never smokers. 
In the 40 years I and II we did the same in the Norwegian counties. Participants  answering 
“No” in the questions “Do you smoke cigarettes daily?” or “Do you smoke cigars daily?” or 
“Do you smoke pipes daily?” and if answering  “No” to  the question “Have you smoked 
cigarettes daily previously?” were categorized as never smokers. 
40 years III: Participants answering “No” to the question “Do you smoke cigarettes daily?” 
Do you smoke cigars daily?” or “Do you smoke pipes daily?”  and not answering the question 
“if you have smoked previously, how long since you quit?”,  then categorized as never 
smoker. 
40 years IV: Participants answering “No” to the questions “Do you smoke cigarettes daily?” 
or “Do you smoke cigars daily?” or “Do you smoke  pipes daily ?” and not answering the 
question “if you have smoked previously, how long since you quit?”, then they are 
categorized as a never smoker. In addition we include the question unique for IV: “Never 
smoked daily?”, then a never smoker. (Brings any records from missing to never, not from 




Oslo: Those answering “No” to the both questions “Do you smoke daily?” and   answering 




Ever-smokers (daily+ former- smokers) 
 
Duration of smoking  
 
The duration of smoking variable was based on two questions. In the CONOR and the Oslo 
health study I, daily and former smokers answered the questions “Numbers of years smoked?” 
In the Norwegian counties study and the 40 years cohort, subjects answering that they were 
ever smokers were asked “How many years all together have you smoked daily?” Duration of 
smoking will be further categorized into three groups (1-29, 30-39 and >40)(Ref: Cigarette 
smoking and risk of colorectal cancer among Norwegian women). Suggestion: Look in EPIC 




Age at smoking initiation  
 
 
The age at smoking initiation variable in CONOR and 40 years III+IV was based on question 
“How old were you when you started smoking”?  
 
In the Norwegian counties study, 40 years I and II cohort and Oslo health study I, this variable 
is constructed. We subtracted total years of smoking from age at enrollment to construct the 





Numbers of cigarettes  
 
The numbers of cigarettes variable was based on question “Numbers of cigarettes smoked 
daily?” in CONOR and Oslo health study I. In  the  Norwegian counties study(I, II and III) 
and 40 years cohort(I,II,III and IV) , ever-smokers were asked “How many cigarettes do you 
smoke/smoked daily?” to extract information on numbers of cigarettes. We will further 
categorized it into three groups (1-9, 10-14 and > 15) (Ref: Gram et al: Cigarette smoking and 
risk of colorectal cancer among Norwegian women). This can be modified during the analysis 





Time since quitting smoking (former smokers only) 
The time since quitting smoking variable was based on question “How long since you have 
quit smoking?” in CONOR, 40 years III and IV. 
Answering option in CONOR and 40 years III and IV was “time in years” continuous 
variable. (rokslutp3 roykslutp4) 
In the Norwegian counties study, Oslo health study I and 40 years I there were four different 
answering options: 
a. Quit since 3 months 
b. Quit since 3 months to 1 year 
c. Quit since 1 to 5 years 
d. Quit for more than 5 years 
 
In 40 years II the question was “If you have smoked previously, how long since you quit” 
with answering options “less than one year” and “more than one year”. (roykslutp2) 
Answers > 60 years is set to missing as outlier (n=4). 
Conclusion: 
 For current smokers “time since quitting smoking” can be handled ok. 
 For former smokers it is a problem for 40 years II because we can only differ between 
<1 year and > 1 year. 
 We decide that former smokers from Norwegian Counties, 40 years I and II and Oslo I 
will be called missing in the continuous variable, but can still be handled as 
categorical variable with four options. 
 
Latency 
We have used information from several variables (see below.). For current smokers the 
information is good. For former smokers, we have information from CONOR and 40 years III 
and IV. The others are set to missing.  
Latency is a constructed variable 
 Latency for current smokers: 
 
a. Years between smoking initiation and cohort enrollment(latency 1) 
or 
b. Years between smoking initiation and censoring/failures(latency 2) 
 
For former-smokers 





In some of the surveys, like in the Norwegian counties study 40 years I+II and 
Oslo health study I, we have “time since quitting” variable which was used for 
constructing latency for former-smokers was available only in four different 
options as: 
1. Less than three months 
2. Three months to 1 year 
3. 1 year to 5 years 
4. 5 years to more 
 
Our main goal was to create a continuous latency variable which was not 




a. Latency  
Latency  1 (Total years from smoking initiation and quitting or cohort enrollment – 
current smokers only) 
b. Latency 2 (Total years between smoking initiation to failure/censoring – current 
smokers only) 
 
c. Latency 3  (Total years between smoking initiation and quitting or cohort 
enrollment- former smokers only)  
“Only for CONOR, 40 years III and IV” 
 
# missing here includes if participants are from other surveys rather than CONOR, 
40 years III and IV”.  
 
d. Latency 4 (Total years between smoking initiation to failure/censuring – former  
smokers only) 




Pack- years of smoking 
This is calculated as number of cigarettes smoked per day, divided by 20 and multiplied by 










The “pipe_smoker_sc” variable yes/no comes from all our surveys.  
 
The amount of pipe smoking ( packs pr week ) will come from 3C I, II, III, 40Y I, II, and Oslo 
I.  Variable name “number_pipetobacco_sc”. 
 
In Oslo 1 they only ask about nr of packs in 3 categories. We have estimated that if answering 
0-0,5 pack will be 0,25 pack, 1-2 packs will be 1,25 and 2 packs will be 2 packs. Then they 
are categorized in the variable “number_pipetobacco_sc”.  
 
Further, if any answer then considered “yes”, if no answer then considered “no”, in the 
“pipe_smoker_sc” variable. 
 







Alcohol Variables  
 
The alcohol variables are from the CONOR and the 40 years study III and IV. The 40 years 




In CONOR and 40 years study III and IV the question was “are you a teetotaler?” and there 
was a “yes/no” answering option.  
We have added the persons who are light/moderate/heavy drinker from the “alcohol 




Our alcohol frequency variable is constructed to become a light, moderate  and heavy (n=42, 
drinker as categorical variable. In general, we have considered a heavy drinker to drink more 




In the CONOR study the variable “drinking pattern” is a 1 to 5 categorical variable: 1. 
Drinking more than once a week 2. Drinking once a week. 3. 2-3 times pr month 4. Once a 
month. 5. Less than once a month. The following categorization has been made: if answering 
1 in CONOR, then categorized as heavy drinker. If answering 2 in Conor, then categorized as 
a moderate drinker. In answering 3,4 or 5 in CONOR, then categorized as a light drinker. 
 
40 years 
There is no information about alcohol consumption in 40 years I and II. In 40 years III and IV 




more pr week, then categorized as a heavy drinker. If drinking 4 times pr month (once a 
week) then categorized as a moderate drinker. If drinking less, then categorized as a light 
drinker. 
 




Alcohol grams pr day  
 
This variable has been constructed from information about drinking frequency and type of 
drink. According to the (ref: www.fhi.no), one glass of wine equals 14,4 grams of pure 
alcohol, one glass of beer equals 11,9 grams of pure alcohol, and one glass of spirits equals 
12,8 grams of pure alcohol. Values larger than 100 grams pr day has been considered 
extreme, and have been set to missing (n=12). 
 
CONOR 
In CONOR the question was “how many glasses of wine / beer / spirits do you drink in a two 
weeks period?” The calculated amount of grams was divided on 14, to get the alcohol 
consumption per day. 
 
40 years 
In 40 years III and IV the question was “how many glasses of wine / beer / spirits do you 




Height and weight were recorded at the health station for all participants, and body mass 
index (BMI) was calculated by standard formula (ref). Observations with extreme values for 
height and weight were set to missing as follows: height <100 or >250 cm, weight <35 or 
>250 kg, BMI <15 or >60 kg/m2.(Ref: T Stocks Me-Can Cohort Profile 2009). 
 






In the analysis we will collapse category 1 and 2 due to low number in category 1 (1.17%) 















Women were categorized as pre-, peri- or postmenopausal. Only 10 per cent of our cohort was 
equal to, or older than 48 years old at inclusion, therefore most in our cohort was 
premenopausal at inclusion.  
 
Questions about menopause were present in CONOR and 40 years III and IV as a continuous 
variable “age at menopause”. In the County Study and in 40 years I and II, this was a question 
with 6 options: “  
1=Ja, menopause inntrådt 
2=Nei, menopause ikke inntrådt 





Answering 1 and 6 were classified as postmenopausal, 2 and 4 were premenopausal, 3 and 5 
were uncertain and classified as the other missing according to age (see below): 
 
If missing information, women were classified as premenopausal if they were less than 46 
years of age. If they were older than 55 years of age, they were classified as postmenopausal. 
Women who were between 46 and 55 years of age were classified as perimenopausal / 
unknown. (Ref: EPIC).  
 
Oral contraceptive use (woman only) 
 
We made the variable “oral contraceptive use” a binary variable (ever / never). In CONOR it 
was reported in questionnaires as current, former or never user, and the current and former 
category were collapsed into ever user by us. There is no information about OC in the County 
Study. 
In the 40 years study, this information was initially collected through interviews, later from 
questionnaires. Due to inconsistent information from several of these studies, we have only 
used information from 40 year III in our study. This is in accordance with advice from tex. 
Anders. 
 
Post- menopausal hormonal therapy (PMHT) (women only) 
 
Post-menopausal hormonal therapy (PMHT) in CONOR was 5 category options, with 
different answering options for never users, former users, and for users of PHT with or 
without prescriptions. In the 40 years study, the answering options were ever, former, never. 




Menarche (women only) 
 
Age at menarche was categorized as a continuous variable. Information about menarche is in 
CONOR and 40 years III and IV. 
 





Women reporting menarche at age 6 years old or less (n=9), or 22 years old or more (n=31), 
were set to missing. 
 
 
Parity (women only) 
 
Information about parity was provided by the Statistics Norway, and is the reported number of 




Age at first childbirth (women only) 
 
Variable created from information provided by the SSB, which provided the year for the 
persons first child, and birth year. 





Smoking exposure before first childbirth (woman only) 
 
Year at first childbirth was given by the SSB. 
Age at smoking initiation is a continuous variable in CONOR and 40 years III and IV. 
 
The age at smoking initiation variable in CONOR and 40 years III+IV was based on question 
“How old were you when you started smoking”?  
 
In the Norwegian counties study, 4o years I and II cohort and Oslo health study I, this variable 
is constructed. We subtracted total years of smoking from age at enrollment to construct the 
age at smoking initiation. This variable was available for both daily and former smokers. 
 
We therefore have good information about smoking exposure before first childbirth, for both 
former and current smokers.  
 
Formulas: 
1. Year of survey assessment – total years of smoking = year of smoking initiation  
  Year of smoking initiation – year of birth = age at smoking initiation 
 
2. Age at enrollment - total years of smoking = age at smoking initiation 
 
 
Total: Age at smoking intiation 
 
 
Year first childbirth – year smoking initiation = years of smoking before first childbirth 
 
Excluded: 





- Smokers initiating after first childbirth 
- No parity 
 
 
In the variable exposure_before_first_childbirth are those with negative number (ie those 





The physical activity variable was created as a 1 to 4 categorical variable, with the variable 
description from CONOR as a reference: 1. Reading, watch TV, other sedentary activity, etc. 
2. Walking, bicycling, etc. 3. Light sports, heavy gardening > 4 hours pr week. 4. Hard 
exercise, competitive sports regularly. In all the included studies except 40 years III, there 
were a 1 to 4 categorical variable.  
 
In the 40 years III, there were two questions for physical activity: “how much light activity do 
you do pr week?”, and “how much heavy activity do you do pr week”, with a 1 to 4 answering 
option for both questions.  
 
If answering 1 or 2 to I aktiv then 1 
3 or 4 to Iaktiv then 2 
1 or 2 to h_aktiv then 3 





Group 1: Light physical 
Group 2: Mild physical activity 
Group 3: Moderate physical activity 





We have information about education level from SSB, and the 1970, 1980 and 1990 census. 
By consensus, we decide to use the highest level of education from the 1980 or 1990 census. 
If the information is missing, then we use the 1970 census. If no information from any census, 
then real missing. 
 
Educational level was given in 1-8 categorical variables from SSB. Value 9 is not answered or 
unknown level of education:  
 
1. 7 years primary school 
2. 9-10 years primary/secondary school 
3. Technical school, middle school, vocational school, 1-2 years senior school 
5. University or university college level 1     
6. University or university college level 2   




8. University researcher level   
 
9. Not answered or unknown level of education 
 
These were merged into four levels of education as follows:  
 
1:  1 and 2 low education level 
2: 3 and 4 low/medium education level 
3: 5 and 6 medium/high education level 
4: 7 and 8 high education level 
 





As for education, information provided by SSB from the 1970, 1980, 1990. Information about 
income was categorized in different ways in the different census, which makes it difficult to 
compare the different time periods. 
 
Income was categorized as follows: Distribution of all incomes at one census was categorized 
in quartiles. The first quartile was given value 1, the second quartile was given value 2, the 
third quartile was given 3, and the fourth quartile was given 4. This was done for all three 
census independently. 
 
The highest quartile registered at either census counted for that individual. The income files 





To create four groups for socioeconomic status (SES), income and education categories were 
added. The sum classified the individuals as follows:  
 
A) 2 score= SES group 1 
B) 3 and 4 score = SES group 2 
C) 5 and 6 score= SES group 3 
D) 7 and 8 score= SES group 4 
 
Comment: we suggest creating 3 SES groups instead of 4. The reason for this is that the 
groups 2 and 3 will be very homogenous, if we create 4 categories.  
 
If we create 3 categories, we will have a low, middle and high SES category, which is a 
common way of classifying social groups. It probably gives a more correct picture of the data, 
as the most important issue about SES will be to differ between low and high SES. We 
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